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Chapter 1 
Bioimaging with Fluorinated Contrast Agents 
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1.1 Fluorinated Compounds in Medicine 
Fluorinated polymers and emulsions are earning a place as tools for a 
variety of biomedical applications, including oxygen carriers (“artificial 
blood”), contrast agents for imaging, and drug delivery vehicles.1, 2 
Additionally, fluorination of drugs is a common means to impart metabolic 
stability and enhance tissue permeability, for example through the blood 
brain barrier.3  Over the years, research in fluorinated drugs and 
biomaterials has resulted in a variety of novel fluorinated compounds and 
emulsions. 
 Fluorinated compounds are of great interest to the biomedical 
community due to their multiple unique properties.  Introducing fluorine 
into a molecule generates novel behavior due to the high ionization 
potential, high electronegativity (4.0 on the Pauling scale), and low 
polarizability of this atom.4  Fluorine has a van der Waals radius of 1.47 Å, 
making it larger than hydrogen, which has a van der Waals radius of 1.20 
Å.5  Fluorine is as space filling as oxygen, yet is much less polarizable.  
Perfluorocarbons have a larger cross section than their hydrocarbon 
counterparts due to the larger size of fluorine, and have a helical structure 
rather than the planar, zig-zag structure common to hydrocarbons.  
Additionally, the conformational freedom of perfluorocarbons is reduced 
due to their greater gauche/trans interchange energy (4.6 kJmol-1) than 
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hydrocarbons (2.0 kJmol-1).  As a consequence, the occurrence of gauche 
defects is reduced, thereby facilitating stacking and ordering of 
fluorocarbon chains at equilibrium conditions.1, 6, 7 
 One of the most fascinating properties of fluorinated compounds is 
their simultaneous hydrophobicity and lipophobicity.  This promotes self-
aggregation, phase separation and the exclusion of non-fluorinated 
materials from fluorinated emulsions.1  These properties are often 
exploited in drug delivery applications, where the increased lipophobicity 
imparted by fluorine facilitates permeation of the blood brain barrier (BBB), 
especially in neuroleptics and selective serotonin reuptake inhibitors 
(SSRI) such as fluoxetine, citalopram, and paroxetine.3 
 Perfluorocarbons are some of the most thermally stable 
compounds known and are highly chemically inert due to the strength of 
the C-F bond, which is the strongest single bond known in organic 
chemistry.  The electronegativity of fluorine reinforces the carbon 
backbone of perfluorocarbons, and creates a compact electron shield that 
protects the carbon-carbon bonds from approaching reagents.1  Because 
of this stability, perfluorocarbons typically do not detrimentally interact with 
cells and tissues.  Studies have shown that fluorinated surfactants 
consistently exhibit lower hemolytic activity than their hydrogenated 
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counterparts, although their pharmacokinetics and potential chronic 
toxicity still need to be evaluated.8, 9 
 In contrast to their strong intramolecular bonds, perfluorocarbons 
exhibit very low intermolecular cohesion.  The low polarizability of fluorine 
results in lower van der Waals interactions between molecules, thus 
reducing their attractiveness to one another.  Thus, liquid perfluorocarbons 
behave nearly like an ideal gas.1  Fluorinated liquids have high vapor 
pressures compared to their corresponding hydrocarbons, making them a 
strong candidate for use in gas-filled microbubbles, which have been 
demonstrated as ultrasound contrast agents.1, 2  Additionally, their weak 
intermolecular cohesion gives perfluorocarbons extremely high oxygen 
and carbon dioxide dissolving capacities that are on the order of 50 vol % 
and 200 vol %, respectively.1  This property makes them suitable for use 
in “artificial blood” applications, which could help mitigate allogeneic blood 
shortages and, in the future, may make them useful as a preservative to 
prevent organ hypoxia prior to transplantation.1, 2 
 In addition to the novel chemical properties it endows to 
fluorocarbons, fluorine also has interesting nuclear properties that are 
biologically relevant.  Fluorine is a monoisotopic element, meaning that it 
has only one stable isotope found in nature, fluorine-19.  The high 
abundance of fluorine-19 compared to other fluorine isotopes, combined 
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with the fact that fluorine-19 has a net magnetic moment (due to its odd 
number of neutrons and protons), make fluorine-19 ideally suited for use 
as a nuclear magnetic resonance imaging (MRI) contrast agent.10, 11 
A synthetic isotope of fluorine commonly used in medical imaging is 
fluorine-18. This isotope is used in positron emission tomography (PET) 
imaging and has a half-life of approximately 110 minutes and decays via 
positron emission (β+) to oxygen-18.  The relatively long half-life of 
fluorine-18 and its decay into a non-toxic daughter nucleus make it ideal 
for PET imaging. 10, 12 
Secondary ion mass spectrometry (SIMS) imaging is an emerging 
in vitro imaging technique that could utilize fluorinated contrast agents.  
SIMS is a mass spectrometry technique that can be used to generate a 
mass image of a surface.13  Recently it has been gaining interest as a 
bioimaging technique looking at cells and tissue samples for diagnostic 
applications.14, 15  Fluorinated contrast agents would be useful in SIMS 
imaging because of fluorine’s anomalously high ion yield with this 
technique, whereby it can be easily detected.16  Combined with fluorine’s 
biological rarity, this suggests that fluorinated contrast agents could be 
designed to target specific cell markers with fluorine acting as a SIMS 
“chromophore.”  A detailed description of SIMS imaging can be found in 
Appendix C.  
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1.2 Positron Emission Tomography (PET) 
Basics of Positron Emission Tomography: Positron Emission Tomography 
(PET) is a gamma imaging technique that utilizes positron-emitting 
radionuclides as a gamma ray source.  As the radionuclide decays, a 
positron (β+) is expelled from the nucleus and travels a short distance in 
the surrounding tissue before it encounters an electron, at which time both 
particles annihilate each other.10, 17  The distance traveled by the positron 
is known as the positron range, and is typically around 1 mm.17  Each 
annihilation event produces two 511 keV gamma photons that travel in 
opposite directions.  The energies of the gamma photons correspond to 
the rest masses of the electron and positron, which are completely 
converted to energy.17  The gamma rays are detected by an array of 
detectors surrounding the patient, which are electronically linked such that 
two detection events unambiguously occurring within a certain time frame 
are determined to be coincident and hence originated from the same 
annihilation event.  These coincidence events are then reconstructed to 
give spatial information on the distribution of the radionuclide throughout 
the body.10, 17 
In a typical PET imaging procedure, a gamma emitting contrast 
agent is intravenously injected and allowed to reach a steady state 
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concentration in the tissues of interest.  Typical contrast agents include 
gallium-68, iodine-124, oxygen-15, and fluorine-18.10, 17, 18  By far the most 
commonly used contrast agent in PET imaging is fluorine-18 due to its 
long half-life (~110 min).  Fluorine-18 is delivered as a 
radiopharmaceutical; combined with glucose to form 18F-
fluorodeoxyglucose, shown in Figure 1.1. 
 
Figure 1.1: 18F-Fluorodeoxyglucose 
 
18F-Fluorodeoxyglucose (FDG) accumulates rapidly in cells that utilize 
large quantities of glucose, such as neurons, myocytes, and cancerous 
cells.  Being an analog of D-glucose, FDG is phosphorylated by 
hexokinase to 18F-FDG-6-phosphate after cellular uptake, preventing it 
from leaving the cell.19  The 2’ hydroxyl group in glucose is necessary for 
continued glycolysis after the first phosphorylation step, but has been 
replaced by 18F in FDG.  Thus, FDG cannot be completely metabolized 
until radioactive decay occurs, at which point 18F decays by positron 
emission into the stable isotope 18O, which is subsequently protonated to 
a hydroxyl to allow for normal metabolism of the resultant D-glucose-6-
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phosphate.  As a result, the physiological distribution of FDG is a good 
measure of cellular glucose metabolism.  For this reason, it is commonly 
used for tumor imaging to reveal regions of metabolically active tissue that 
could indicate cancer.19 
 
18F Radiopharmaceutical Production: 18F-Fluorodeoxyglucose is 
synthesized using 18F-, which is produced in a dedicated medical cyclotron 
using the 18O(p,n)18F nuclear reaction.18  In this reaction, protons bombard 
18O enriched water to produce 18F- anions via the following reaction: 
 
 
In this reaction, the 18O nucleus accepts a proton, increasing its atomic 
number by one to fluorine.  The mass number remains the same with the 
ejection of a neutron.  After the 18F- ions are produced, they are collected 
in an ion exchange resin prior to synthesis of 18F-FDG.18  The FDG 
radiopharmaceutical is then produced via a nucleophilic substitution 
reaction between a cryptand-reinforced fluoride anion and a triflated and 
protected glucose derivative in acetonitrile, according to Figure 1.2. 
 
onFpO +→+ −+ 89
18
8
1
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Figure 1.2: 18F-fluorodeoxyglucose synthesis 
 
In this reaction, the hydroxyl groups of the glucose molecule are protected 
by acetate groups, and the 2’ hydroxyl group is activated for nucleophilic 
attack by the triflate (OTf) functional group.  The potassium fluoride-K222 
reagent is the 18F fluoride salt, in this example bound to Kryptofix-222 
(K222) as the cryptand.18  After deprotection of the hydroxyl groups with 
NaOH, the resulting 18F-fluorodeoxyglucose is ready for patient 
administration. 
 A new technique to incorporate fluorine-18 into a nanoparticle 
carrier for PET imaging has been reported by Matson and Grubbs.12  In 
this technique, amphiphilic block copolymers created using ring opening 
metathesis polymerization (ROMP) were assembled into micelles in 
aqueous solution and crosslinked via a photochemical reaction, after 
which they were radiofluorinated.  Polyethylene glycol (PEG) was used as 
the hydrophilic component of the copolymer due to its non-immunogenic 
nature, and mesylate leaving groups were added to the PEG for eventual 
displacement by the fluorine-18 functionality.  A monomer containing a 
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cinnamoyl group was selected as the hydrophobic monomer to facilitate 
photocrosslinking.  Fluorine-18 was then conjugated to the end of the 
hydrophilic block to replace the mesylate leaving group.  This technique 
produced particles between 47 nm and 142 nm that might be suitable for 
passive targeting of tumors.12  A technique like this may provide more 
selective targeting of tumors than 18F-FDG, which will accumulate in any 
tissue with high metabolic activity. 
 In a study by Devaraj et al., a nanoparticle contrast agent for 
concurrent PET and MRI was developed using fluorine-18 as the positron 
source.20  The particles contained an iron oxide core surrounded by 
crosslinked dextran.  A PEG group containing 18F was then conjugated to 
the surface using “click” chemistry.  The authors report that PET imaging 
with the resultant particles showed a very high signal to noise ratio.  The 
MRI/PET combined images suggested that the particles accumulated in 
the spleen, liver, and other lymphatic organs.20  Including the iron oxide as 
an MRI contrast medium enables one to gather spatial information, thus 
providing an anatomical context for the PET data.  The ability to combine 
multiple contrast media is one of the benefits of using nanoparticle-based 
imaging agents instead of traditional small molecule contrast agents. 
 
1.3 Ultrasound Imaging 
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Basics of Ultrasound Imaging: Diagnostic sonography, more commonly 
known as ultrasound imaging, is a medical imaging technique that uses 
high frequency sound to measure and visualize subcutaneous features of 
the body, such as tendons, muscle tissue, and internal organs.10, 21, 22  
Obstetric sonography is commonly used to determine the proper growth 
and development of a fetus during pregnancy.  The term ultrasound refers 
to sound waves with a frequency greater than 20 kHz, which is beyond the 
auditory threshold of humans.10 
 Diagnostic sonography works by focusing ultrasound waves at the 
tissue of interest through a sonic transducer, which is made of a 
piezoelectric material.  The ultrasound beam is focused to a particular 
depth by controlling the geometry of the transducer, or by electronically 
controlling the timing between actuations of separate transducer 
elements.10  As the ultrasound beam intercepts the boundary between two 
materials (e.g. transducer and skin, tissue and air, tissue and bone, etc.), 
a fraction of the sound is reflected as an echo and a fraction is transmitted 
through the boundary.  This proportion depends on the relative acoustic 
impedances of the two materials, which is the product of the material 
density and the velocity of sound in the material.10  If the incident angle of 
ultrasound is 90° to the interface, the reflected fraction of sound energy is 
given by the following equation: 
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Where Zn are the acoustic impedances of the two materials.10  As the 
difference between acoustic impedances increases, the intensity of the 
reflected sound increases, and the contrast of that region increases. 
 Contrast-enhanced ultrasound is a technique that uses ultrasound 
contrast medium to enhance the echogenicity of the region of interest by 
introducing acoustic impedance that is significantly different from typical 
anatomical structures.  Commercially available contrast media are 
composed of gas-filled microbubbles that are intravenously injected prior 
to imaging.  The compressible gas in the microbubbles oscillates when 
insonified, producing an acoustic impedance that is distinctly different from 
that of the surrounding tissue.1, 2, 21, 22  This allows the clinician to 
distinguish blood from the surrounding tissues, and is often used for 
reperfusion imaging and tumor imaging.10 
 
Fluorinated Contrast Agents: Perfluorocarbons are often used as the gas 
phase of ultrasound contrast microbubbles because of their ability to 
stabilize gaseous microbubbles in an aqueous suspension.1, 2, 21, 22  
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Microbubbles that contain air collapse under the combined arterial and 
Laplace pressure and begin to rapidly dissolve in the blood.1, 2  
Conversely, a microbubble composed solely of a perfluorocarbon gas will 
expand in circulation because of gases dissolved in the blood diffusing 
into the perfluorocarbon phase.  For this reason, it is necessary to stabilize 
droplets to prevent changes in size.1, 2 
 A clinical microbubble contrast agent currently available was 
developed by Alliance Pharmaceutical Corporation.  Imagent® is 
formulated as a heat-sterilized, spray-dried powder stored under a 
nitrogen-diluted perfluorohexane atmosphere.  The powder contains 
dimyristoylphosphatidylcholine, hydroxyethylstarch, poloxamer, and salts 
to maintain tonicity.  After suspension in water, the mixture forms a 
phospholipid monolayer that traps the gas mixture in the headspace, 
forming echogenic microbubbles.1, 23 
 For some applications, it is desirable to develop microbubbles that 
will target specific tissue types for imaging.  In one study by Weller et al., 
perfluorobutane-filled microbubbles were synthesized and conjugated with 
antibodies to target intercellular adhesion molecule-1 (ICAM-1), which is 
upregulated in the endothelium at sites of inflammation to facilitate 
migration of circulating leukocytes into the surrounding tissue.24  Human 
coronary endothelial cells were grown to confluence, stimulated to 
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inflammation with interleukin-1β (IL-1β) and incubated with anti-ICAM-1 
antibody conjugated microbubbles.  The authors reported that targeted 
microbubbles detected the presence and severity of endothelial 
dysfunction ranging from normal to maximal inflammation.24 
 In another study, microcapsules were synthesized that contain 
liquid perfluorocarbons as an echogenic medium, which are considerably 
easier to work with than gaseous perfluorocarbons.22  In this method, 
poly(lactic-co-glycolic) acid (PLGA) and liquid perfluorocarbon 
(perfluorooctyl bromide, pefluoropentane, perfluorohexane, 
perfluorooctane, or perfluorodecalin) were dissolved in dichloromethane.  
The organic solution was then emulsified into an aqueous solution 
containing sodium cholate as a surfactant and the organic solvent was 
evaporated.22  Because of the concurrent hydrophobicity and lipophobicity 
of the perfluorocarbon liquid, the emulsion droplets formed a core-shell 
structure with the perfluorocarbon in the center of a PLGA shell stabilized 
by sodium cholate.  The authors were able to obtain both microbubbles 
and nanobubbles with this method, depending on the amount of shear 
applied during the emulsification.22  In a later study, the authors 
synthesized perfluorooctyl bromide-containing bubbles with mean 
diameters ranging between 70 nm and 25 µm.  The authors found that in 
 15
vivo nanocapsule injections produced significant ultrasound enhancement 
of the blood during hepatic imaging.21 
 
1.4 Magnetic Resonance Imaging (MRI) 
Basics of Magnetic Resonance Imaging: Magnetic resonance imaging 
(MRI) is a non-invasive, in vivo imaging technique that utilizes magnetic 
fields to visualize soft tissues within the body.  MRI provides greater 
resolution of soft tissues than CT and x-ray imaging, which makes it 
especially useful in neurological, cardiovascular, and oncological imaging.  
MRI is presumed safer than PET, CT and x-ray imaging because it does 
not utilize ionizing radiation.10 
 MRI uses strong magnetic fields (typically between 0.15 T and 3 T) 
to align the nuclear magnetic moments of magnetically active nuclei in the 
body with an external magnetic field.10  Typical anatomical imaging 
focuses on 1H hydrogen nuclei, which is the most abundant element in the 
body.  When in the presence of an external magnetic field, the magnetic 
moment of the hydrogen nuclei precess around the external magnetic field 
at a frequency (known as the Larmor frequency) that is dependent on the 
gyromagnetic ratio of the nucleus and the strength of the external 
magnetic field, given by: 
ν = γ ⋅ B
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where ν is the Larmor frequency (MHz), γ is the gyromagnetic ratio 
(MHz/T), and B is the magnitude of the external magnetic field.10, 25 
Precession of nuclear magnetic moments is easily described in 
terms of classical physics, but is more accurately described as a quantum 
mechanical process.  The individual nuclear magnetic moments will align 
themselves with the external magnetic field in two degenerate quantum 
states: either parallel or anti-parallel, because of the two possible spin 
states of the nucleus (±½).  The ratio of nuclei in each state is roughly 1:1, 
however the anti-parallel state is slightly more energetic than the parallel 
state.  For this reason, there are generally more nuclei in the parallel state 
than the anti-parallel state, hence there is a net magnetic moment 
generated within the tissue that is parallel to the external magnetic field.  
This vector is denoted as Mo, and precesses at the same frequency as the 
nuclear magnetic moments.  The energy difference between the two 
degenerate states is proportional to the external magnetic field strength; 
hence the magnitude of Mo increases as B increases.10, 25 
In addition to a strong external magnetic field, a transverse 
magnetic field perpendicular to the external field is applied to change the 
direction of the magnetic moment.  This transverse magnetic field 
oscillates at the Larmor frequency of Mo, which enables it to interfere 
constructively with precession.  The net effect is a change in the direction 
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of Mo, with vector components ML in the longitudinal (parallel to the 
external field) direction and MT in the transverse (perpendicular) direction, 
as shown in Figure 1.3.10, 25 
 
 
Figure 1.3: MRI excitation and relaxation phenomena.  Equilibrium 
magnetization (Mo) occurs as magnetic dipoles align with the external 
magnetic field (Bo).  Next, a transverse, oscillating magnetic field (BT) is 
applied that causes a change in the direction of the equilibrium 
magnetization.  This can be decomposed into a longitudinal (ML) and a 
transverse (MT) vector component.  MT decays and ML→ Mo in time as 
functions of the relaxation parameters, T1 and T2.10, 25 
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In time, ML will approach the value of Mo due to random thermal 
motions of the molecule.  This process is called spin-lattice relaxation, and 
the time required for this to occur is called the T1 relaxation time.  
Additionally, MT will decay as Mo is regenerated via entropic interactions 
with other magnetic dipoles.  This process is called spin-spin relaxation, 
and is quantified by the T2 relaxation time.  Both the T1 and T2 relaxation 
times are important parameters used to generate an MR image.10, 25 
Paramagnetic contrast agents are often introduced in MRI to 
enhance image contrast between healthy and diseased tissue or to 
indicate the status of organ function or blood flow.26  Typical agents 
include chelates of Gd3+, Fe3+, or Mn2+.  Paramagnetic contrast agents 
function by reducing the relaxation times of local 1H nuclei through 
magnetic interactions between unpaired electrons and hydrogen nuclei.26  
This causes a local change in contrast, which may be used to distinguish 
between healthy and pathological tissues. 
A detailed description of the physics of magnetic resonance 
imaging is described in Appendix A. 
 
19F Imaging: In addition to paramagnetic MRI contrast enhancement 
techniques, contrast agents based on 19F NMR are emerging as an 
attractive option due to the near-zero background 19F signal, good 
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biocompatibility of fluorinated compounds, and high gyromagnetic ratio of 
fluorine.27, 28  19F imaging has several benefits over paramagnetic contrast 
agents.  Because fluorine is not commonly found in the body, 19F imaging 
offers a high signal to noise ratio.  Additionally, unlike paramagnetic 
contrast agents, which modulate the relaxation times of surrounding 1H 
nuclei, fluorine generates an intrinsic NMR signal.27  For this reason, it can 
be imaged directly and superimposed over an anatomical 1H image.  
Fluorinated contrast agents could be designed that will actively or 
passively target tissues of interest (e.g. tumors, inflammation), and their 
location can then be determined with reference to an anatomical MR 
image that was acquired concurrently.  This property suggests that 19F 
MRI would be similar to PET imaging, although it would not require that 
the patient be exposed to ionizing radiation and would be much less 
expensive. 
 Several studies have validated the concept of 19F MRI contrast 
agent design.  Schwarz et al. used perfluorononane as a gastrointestinal 
contrast agent due to its biological inertness, immiscibility with water, and 
high fluorine content.29  The authors monitored the passage of the 
perfluorocarbon liquid through the GI tract of a mouse using 19F MRI, 
rendering a three dimensional model of the GI tract.  The authors were 
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then able to superimpose these images over conventional 1H MR images 
to provide complimentary anatomical information.29 
 Nanoparticle 19F MRI contrast agents have also been developed 
with some success.  In a study by Du et al., amphiphilic fluoropolymers 
were synthesized using atom transfer radical polymerization (ATRP) and 
their micelles were constructed in water.27  The authors acquired 19F 
phantom images of the particles in solution, which suggested that they 
may be useful as novel contrast agents for a variety of biomedical 
applications.27 
 
Because of its unique properties, fluorine is being utilized in a variety of 
biomedical applications, including imaging agents.  Fluorinated 
compounds have been used in PET imaging, ultrasound imaging, and 
magnetic resonance imaging and are an interesting candidate for use as a 
SIMS contrast agent.  The overall goal of this work is to develop a 
fluorinated nanoparticle that is suitable for use as an in vivo MRI contrast 
agent and a SIMS contrast agent. 
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Chapter 2 
Synthesis and Characterization of Fluorinated 
Nanoparticles for Multimodal Imaging Applications 
 
 22
2.1 Introduction 
Nanomaterials have emerged as valuable tools in biomedical imaging 
techniques, such as magnetic resonance imaging (MRI), fluorescence, 
and positron emission tomography (PET).27, 30-35  Some have been 
designed to serve as multimodal imaging agents, combining seemingly 
disparate techniques such as fluorescence,34 photoacoustic tomography 
(PAT),35 or positron emission tomography (PET)30, 32 with magnetic 
resonance imaging (MRI).  Particles have also been designed that 
combine PET with fluorescence imaging and magnetic resonance imaging 
capabilities.20  Combining different imaging modalities into a single 
contrast agent enables one to capture meaningful images at different 
levels of spatial resolution from the same sample.  Here, the one-step 
synthesis of a colloidally stable, fluorinated polymeric nanoparticle suitable 
for secondary ion mass spectrometry (SIMS) imaging and MRI is reported.  
Fluorine-containing compounds were selected for this application because 
of fluorine’s biological rarity,29 high ion yield in SIMS,16 and magnetic 
activity.29 
SIMS is a technique that is gaining recognition in the area of high 
resolution bioimaging.  In time of flight SIMS (TOF-SIMS), a sample is 
bombarded with an electrostatically focused primary ion beam, causing 
secondary ions to be ejected from the surface.  These ions are then 
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collected in a TOF mass analyzer and a mass spectrum is generated.36  
The primary ion beam can be raster scanned across the sample to record 
a mass spectrum for each pixel.  Ions of interest can be selected from the 
spectra, and the distribution mapped to produce an image of the sample 
surface.  This technique has been used to quantitatively map the 
distribution of a variety of biomolecules in tissues and individual cells,37-42 
and can be used as a diagnostic imaging tool to identify cancer 
biomarkers.43  Developing a contrast agent that binds to cancer cell 
epitopes and generates a strong intrinsic SIMS signal (like fluorinated 
compounds), or enhances the signal of the molecule of interest, would 
help enhance the ability to detect the presence of specific biomarkers.  
Recently, this has been done with gold nanoparticles to enhance the 
signal of cell surface biomolecules.44, 45 
  Fluorinated nanoparticles have also been studied as potential MRI 
contrast agents.27, 30, 32, 33, 46-48  The rarity of physiologic fluorine can be 
exploited to generate highly selective, 19F images that can be 
superimposed over complimentary 1H images, thus providing an 
anatomical context for the fluorinated contrast agent.29, 48, 49  Research in 
this area has focused on the synthesis of fluorinated nanoparticles using a 
variety of different approaches.  Studies have validated the premise of 19F 
MRI using nanoemulsions that contain a perfluorocarbon phase.46, 47, 49-51  
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These studies have used materials such as perfluoro-15-crown-5-ether47, 
50, 51
 or perfluorooctyl bromide49, 51, which is emulsified into an aqueous 
phase using a biocompatible surfactant.  Other studies have created novel 
fluorinated amphiphilic block copolymers that form micelles in aqueous 
solution.12, 27, 32, 33  Typically, a living free radical polymerization method is 
employed to synthesize such amphiphilic block copolymers.12, 27, 33  This 
polymer self assembles in water and the resulting suspension is used as 
the contrast agent. 
Developing particles that have the ability to actively or passively 
target cells or tissues with specific pathologies, such as tumors, could 
enable one to locate tumors or other sites of inflammation with greater 
precision using MRI, or analyze biopsied tumor tissue using SIMS.  One 
possible application of this, in the context of tumor imaging, is to develop 
particles with a long circulation half-life, which could preferentially 
extravasate through the discontinuous endothelium of the tumor and into 
the tumor interstitium, where they would accumulate and provide contrast 
in that region.12, 52 This phenomenon is known as the enhanced 
permeability and retention effect, or EPR effect.53  Another possible 
method is to functionalize the surface of nanoparticles with targeting 
agents, such as antibodies or RNA fragments that specifically bind to the 
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tumor cell epitope.48, 54   MRI can then be used to locate the tumors in 
vivo, and biopsied tumor tissue could potentially be analyzed using SIMS. 
 Although current methods to create fluorinated nanoparticles have 
demonstrated some success, a potential concern is nanoparticle stability.  
For example, the stability of some micellar nanoparticles and lipid-based 
emulsions is dependent on the critical micellar concentration (CMC) of the 
material.12  Concentration can easily be controlled in vitro, but the 
concentration of the particles might vary greatly when introduced into a 
physiological environment, which could disrupt the micelle or 
nanoemulsion stability if the local concentration falls below a critical 
concentration, which could adversely affect in vivo performance.  One 
possible way to overcome this encumbrance is to design a nanoparticle 
with physical stability that is independent of concentration by introducing a 
covalent crosslinker.  Here, the synthesis and characterization of a novel 
fluorinated, polymeric nanoparticle contrast agent containing a covalent 
crosslinker is reported. 
 
2.2 Materials and Methods 
Materials:  All materials were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise stated.  1H,H-perfluoro-n-octyl acrylate was 
purchased from ExFluor Research Corporation (Round Rock, TX).  Vazo-
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52 was purchased from DuPont (Wilmington, DE). Prior to nanoparticle 
synthesis, (1,5-N-vinylformamido) ethyl ether was prepared as previously 
described.55  Impurities were precipitated out of N-vinylformamide using 
absolute ethanol and vacuum filtered prior to use.  All other reagents were 
used as received. 
 
Nanoparticle Synthesis:  Nanoparticles were synthesized using a free 
radical polymerization technique.  First, 10 µL of 1H,H-perfluoro-n-octyl 
acrylate, 3.5 µL of N-vinylformamide, 7 µL of (1,5-N-vinylformamido) ethyl 
ether, and 0.005 g of (E)-2,2’-(diazene-1,2-diyl)bis(2,4-
dimethylpentanenitrile) (Vazo-52) were added to absolute ethanol 
containing 0.018 g/mL polyvinylpyrrolidone (MW approximately 360 kDa).  
The reagent mixture was sparged for 10 min with argon to remove 
dissolved oxygen, then heated in a silicone oil bath to 50 °C and stirred at 
approximately 900 rpm.  The reaction was carried out under an argon 
atmosphere for 24 h.  The product was then dialyzed against deionized 
water using a 1 kDa MWCO regenerated cellulose ester dialysis tube for 
24 h.  The dialysate was changed 5 times to ensure complete solvent 
exchange.  Particle suspensions were then centrifuged twice at 15,000 
rpm for 45 min.  The pellet was collected each time and resuspended in 
deionized water.  The reaction scheme is shown in Figure 2.1. 
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Figure 2.1: The top scheme depicts the nanoparticle synthesis.  The 
middle scheme depicts the proposed interaction between fluorinated side 
chains (blue) as the product is transferred from ethanol to water and 
transitions from transparent to turbid.  The photograph inset shows (A) 
reagent mixture prior to reaction, (B) product in ethanol after reaction, and 
(C) nanoparticle suspension in water after dialysis.  (PVP: 
polyvinylpyrrolidone.) 
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Characterization of Nanoparticles:  The size and zeta potential of the 
nanoparticles were determined using dynamic light scattering (ZetaPals, 
Brookhaven Instruments).  All measurements were taken 5 times.  
Measurements are reported as the mean ± standard uncertainty.  ESEM 
experiments were performed using an FEI Quanta field emission 
environmental scanning electron microscope.  Samples were prepared by 
decanting a small volume of nanoparticles suspended in deionized water 
onto a polished silicon wafer and allowing the water to evaporate under a 
fume hood.  Samples were sputter coated with 5 nm of gold prior to 
imaging.  All samples were analyzed using an acceleration voltage of 10 
keV under high vacuum. 
 
Time of Flight Secondary Ion Mass Spectrometry (TOF-SIMS):  TOF-
SIMS was used to analyze the surface chemistry of the nanoparticles (Ion-
TOF IV).  Samples were prepared by decanting a small volume of 
nanoparticles suspended in deionized water onto a polished silicon wafer 
and allowing the water to evaporate under a fume hood.  TOF-SIMS 
experiments were performed on an Ion-TOF IV instrument equipped with 
both Bi (Bin+, where n = 1 to 7) and SF5+ primary ion beam cluster 
sources.  The analysis source was a pulsed, 25 keV bismuth cluster ion 
source (Bi3+), which bombarded the surface at an incident angle of 45 
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degrees to the surface normal.  The target current was maintained at 
approximately 0.3 pA (± 10%) pulsed current with a raster size of 200 µm 
x 200 µm for all experiments.  Both positive and negative secondary ions 
were extracted from the sample into a reflectron-type time of flight mass 
spectrometer.  The secondary ions were then detected by a microchannel 
plate detector with a post-acceleration energy of 10 kV.  A low energy 
electron flood gun was utilized for charge neutralization in the analysis 
mode.  Each spectrum was averaged over a 60 s time period, with a cycle 
time of 100 µs.  These conditions resulted in accumulated Bi3+ ion doses 
that were well below 1013 ions/cm2. 
 
FTIR Reflection Spectroscopy:  FTIR spectroscopy was used to 
qualitatively determine the identity of functional groups present within the 
nanoparticles (Smiths Illuminate FTIR Microscope).  All experiments were 
done on a diamond attenuated total reflectance objective microscope 
accessory.  Reported spectra are the average of 128 scans. 
 
Solid State 19F-NMR Spectroscopy:  The solid-state NMR (ssNMR) 
spectra were obtained on a 3-channel Chemagnetics spectrometer 
operating at 284.0 MHz for 19F and 301.9 MHz for 1H using an 1H/19F 
probe.  The sample was packed in a 4 mm zirconia rotor with Torlon™ 
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endcaps and Vespel™ drivetips and rotated at 10,000 kHz.  The NMR 
spectrum was obtained using H-F cross polarization and a sweep width of 
100 kHz.  A total of 1024 scans were obtained with a dwell time of 10 µs.  
The chemical shift reference was set at -121.1 ppm using Teflon™  
Interference from the Teflon™ endcaps was not subtracted because it was 
negligible under these conditions. 
 
2.3 Results and Discussion 
Fluorinated nanoparticles were synthesized using a single step, free 
radical polymerization method and then precipitated in water.  In this 
method, N-vinylformamide, (1,5-N-vinylformamido) ethyl ether, and 1H,H-
perfluoro-n-octyl acrylate were added to a solution of polyvinylpyrrolidone 
(PVP) in ethanol (Figure 2.1).  Vazo-52 was added as an initiator, and the 
solution was sparged with argon.  The reaction was carried out at 50 ºC 
for 24 hours.  Particles were prepared without PVP under the same 
conditions to serve as a control group.  These particles were larger than 
the particles prepared in the presence of PVP and were not used in further 
analysis.  The product was then dialyzed against deionized water to 
induce particle precipitation, and then centrifuged and resuspended twice 
in water (Figure 2.1). 
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The nanoparticles had a size distribution with maxima at 250 nm 
and 700 nm according to dynamic light scattering.  After adding Tween-20 
(final concentration: 5.0 x 10-4 g/mL) and sonicating for 4 h, the distribution 
maxima shifted to 250 nm and 575 nm (Figure 2.2).  Environmental 
scanning electron microscopy (ESEM) imaging suggested that the 
particles were substantially smaller than 500 nm (Figure 2.2).  The 
disparity between the ESEM and the DLS data could be partially due to 
swelling of the particles in aqueous medium, but is most likely due to 
flocculation occurring in water, which would increase the particle size 
observed by DLS.  DLS measurements taken of the product in ethanol 
after polymerization were indistinguishable from the background, 
suggesting that the product was soluble.  After precipitation in water and 
solvent exchange, particles demonstrated excellent colloidal stability, and 
showed only minor settling when left undisturbed at room temperature for 
more than five months.  This settling was easily reversed by lightly 
shaking the vial for several seconds. 
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Figure 2.2: (A) ESEM images of the fluorinated nanoparticles, which 
appear as white spheres and ellipsoids.  Image analysis using Image-Pro 
software revealed a mean particle size of 47.0 nm ± 3.6 nm (95% 
confidence level).  (B) Dynamic light scattering measurements of 
fluorinated nanoparticles under different conditions; (top) size as a 
function of nanoparticle concentration, (bottom) effect of Tween-20 and 
sonication on particle size.  Under shear and in the presence of the 
surfactant, particle flocculation is reduced.  The lines represent the 
cumulative distribution function. 
 
Fourier Transform Infrared Spectroscopy (FTIR) was used to 
determine the functional groups present in the particles (Figure 2.3).  The 
spectra for the nanoparticles showed bands corresponding to both amide I 
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(1670 cm-1 – 1650 cm-1) and amide III (1315 cm-1 – 1250 cm-1) peaks.  
The spectra also showed a second peak in the carbonyl region (1690 cm-1 
– 1760 cm-1), as well as peaks in the ester region (1080 cm-1 – 1300 cm-1), 
which were due to the presence of the fluorinated ester group.  These 
peaks were present in the spectra from particles prepared both with and 
without PVP surfactant, indicating that they originated from the particles 
themselves and were not solely an artifact from the γ-lactam groups 
present in residual PVP. 
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Figure 2.3: FTIR spectrum of fluorinated nanoparticles.  The spectrum for 
(A) PVP is compared to (B) particles synthesized in the presence of PVP 
and (C) particles synthesized without PVP.  Both spectra (B) and (C) show 
amide I and amide III peaks, suggesting that N-vinylformamide (NVF) is 
incorporated into the particles.  Spectra (B) and (C) also show carbonyl 
peaks and ester peaks, suggesting the presence of the fluorinated ester 
acrylate group. 
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TOF-SIMS experiments suggested the presence of fluorinated 
groups on the surface of the particles (Figure 2.4), indicating they would 
be a suitable agent for cellular imaging applications.  SIMS has a sampling 
depth of approximately 1 nm in polymeric materials,56-58 suggesting that 
some of the fluorinated side chains were present on the surface of the 
particles.  Spectra also indicated the presence of nitrogen-containing 
groups, which could be from the N-vinylformamide side chain, the (1,5-N-
vinylformamido) ethyl ether crosslinker, or residual PVP surfactant.  
Regardless of their source, the nitrogen-containing groups provided the 
particles with a hydrophilic surface character, which may contribute to their 
aqueous stability. 
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Figure 2.4: Negative secondary ion mass spectra for nanoparticle samples 
suggest the presence of nitrogen-containing functional groups and 
fluorinated groups on the surface of the particles. 
 
The presence of fluorinated groups on the surface of the particles 
could help explain the disparity between the particle sizes measured with 
dynamic light scattering and the sizes suggested from the ESEM 
experiments.  The fluorinated groups are extremely hydrophobic, and it is 
probable that their presence on the particles’ surface would induce 
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flocculation due to hydrophobic interactions.  This phenomenon would be 
in competition with the repulsive effects of the hydrophilic groups on the 
particles’ surface.  DLS experiments showed changes in measured 
particle size as particle concentration was varied, which suggests that 
flocculation was occurring (Figure 2.2).  Additionally, sonication and the 
addition of Tween-20 (final concentration: 5.0 x 10-4 g/mL) were shown to 
decrease the effect of flocculation. 
Solid-state 19F-NMR (ssNMR) was used to help further elucidate 
the structure of the particles and validate their use as MRI contrast agents 
(Figure 2.5).  The locations of the peaks were consistent with the 
presence of two different fluorine-containing sites within the fluorinated 
group.  The peak at -82.1 ppm originates from CF3 fluorine and the one at 
-122.8 from CF2 fluorine, which is overlapped with spinning sidebands.  
This is consistent with the structure of the 1H,H-perfluoro-n-octyl acrylate 
monomer.  The spectrum suggests that in vivo studies will require 
selective excitation due to the different fluorine chemical shifts present in 
the particles.11, 27 
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Figure 2.5: The solid state 19F NMR spectrum of the fluorinated 
nanoparticles reveals peaks consistent with the presence of two different 
fluorine-containing sites in the fluorinated group.  The peak at -82.1 ppm 
originates from CF3 fluorine, and the one at -122.8 ppm from CF2 fluorine.  
The CF2 peak is surrounded by spinning sidebands. 
 
Developing fluorinated nanoparticles for multimodal 19F-MRI and 
SIMS imaging that possess intrinsic colloidal stability represents a largely 
unexplored research area.  Here, particles less than 500 nm in diameter 
were synthesized using free radical polymerization, followed by 
precipitation.  Secondary ion mass spectrometry was used to determine 
the chemical properties of the particles’ surface, which will greatly impact 
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their colloidal stability and cytotoxicity.  The strong fluorine signal indicated 
that the particles would be suitable for SIMS imaging applications.  We 
hypothesize that the inclusion of hydrophilic monomers in the 
polymerization process enhances their colloidal stability and helps prevent 
irreversible agglomeration that might otherwise occur due to the 
fluorinated groups.  Hypothetically, this technology could be extended to 
include degradable monomers or crosslinkers,59, 60 or PEG acrylates to 
improve their properties.  Ongoing studies will evaluate the performance of 
the nanoparticles as MRI contrast agents both in vitro and in vivo, as well 
as the suitability of the particles for cellular level imaging using SIMS. 
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Chapter 3 
Analysis of a Nanoparticle Contrast Agent Using Small 
Angle Neutron Scattering (SANS) 
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3.1 Introduction 
 Magnetic resonance imaging (MRI) is a powerful diagnostic 
imaging tool that is both noninvasive and nondestructive.  Paramagnetic 
contrast agents, such as gadolinium chelates, are often used to accelerate 
proton relaxation and can be employed to reveal features that might 
otherwise be obscured as a result of similarities in the relaxation times of 
adjacent tissues.26, 27, 31  Although MRI has been an effective diagnostic 
tool, often the contrast changes are ambiguous and difficult to interpret.  
Additionally, the biological impact of traditional Gd3+ ion chelates, 
particularly macromolecular agents, is poorly understood.61  To overcome 
these challenges, there has been intense interest in developing contrast 
media containing biologically rare, magnetically active nuclei, such as 
fluorine.27, 30, 32, 33, 46-48  Fluorinated materials are an excellent choice for 
this application because of fluorine’s biological rarity and magnetic 
properties, and because of the excellent biocompatibility demonstrated by 
fluorinated colloids.1, 2, 28  In principle, the rarity in physiological fluorine 
can be exploited to generate highly-selective 19F images that can be 
superimposed over complimentary 1H images, providing an anatomical 
context for the fluorinated contrast agent.29, 49  Additionally, developing 
nanoparticle-based contrast agents that have the ability to actively or 
passively target tissues with specific pathologies, such as tumor tissue 
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and atherosclerotic plaques, could enable clinicians to better diagnose 
such conditions using MRI. 
A specific example of an active targeting strategy involves 
conjugating nanoparticles with ligands that specifically bind cellular 
antigens associated with a pathological state of interest.  This technique 
may amplify the specificity of nanoparticles to the target site.62, 63  A 
potential passive targeting strategy that may be specifically applicable to 
tumor targeting exploits the anatomical and physiological abnormalities of 
tumor vasculature that compromise lymphatic drainage and cause leakage 
of macromolecular agents and nanoparticles into the tumor interstitium.  
This phenomenon is known as the enhanced permeability and retention 
effect, or EPR effect, and can potentially be exploited by controlling the 
nanoparticle size.63-67 
This study aims to develop fluorinated nanoparticles that exhibit 
magnetic activity and therefore might be suitable for biomedical imaging 
using 19F-MRI.63  Nanoparticles were synthesized using two different 
fluorinated monomers, which were compared using neutron scattering and 
19F-NMR.  Amide groups on the nanoparticles were then hydrolyzed to 
their corresponding amines at high pH.  Linear polymers prepared without 
the covalent crosslinker were hydrolyzed as a comparison.   The results 
indicated that both particle types were approximately 500 nm or smaller in 
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diameter, and that they generated a significant 19F-NMR signal, which 
suggested they might be suitable for imaging using 19F-MRI.  Additionally, 
FTIR spectra indicated that amide groups on the particles were hydrolyzed 
to amines at high pH, which suggested they can be conjugated with 
ligands for active targeting strategies. 
 
3.2 Materials and Methods 
Materials:  All materials were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise stated.  1H,H-perfluoro-n-octyl acrylate was 
purchased from ExFluor Research Corporation (Round Rock, TX).  2-
(allyl)hexafluoroisopropanol was purchased from Matrix Scientific 
(Columbia, SC).  Vazo-52 was purchased from DuPont (Wilmington, DE).  
Dialysis membranes were purchased from Spectrum Labs (Rancho 
Dominquez, CA).  Prior to nanoparticle synthesis, (1,5-N-vinylformamido) 
ethyl ether was synthesized as previously described.55  Impurities were 
precipitated out of N-vinylformamide using absolute ethanol prior to use.  
All other reagents were used as received. 
 
Synthesis of Fluorinated Nanoparticles:  Nanoparticles were synthesized 
using a free radical polymerization technique as described previously.68  
First, 20 µL of N-vinylformamide, 20 µL of (1,5-N-vinylformamido) ethyl 
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ether, and 20 µL of the fluorinated monomer (either 1H,H-perfluoro-n-octyl 
acrylate, or 2-(allyl)hexafluoroisopropanol) were dissolved in absolute 
ethanol containing 0.015 mg/mL polyvinylpyrrolidone (PVP) as a 
surfactant (MW approximately 360 kDa).  Next, 6.9 mg of (E)-2,2’-
(diazene-1,2-diyl)bis(2,4-dimethylpentanenitrile) (Vazo-52) were added to 
the solution as an initiator (Figure 3.1). 
 
 
Figure 3.1: Diagram of the reaction scheme.  For each batch, one of the 
fluorinated monomers was reacted with (1,5-N-vinylformamido) ethyl ether 
and N-vinylformamide to generate nanoparticles.  The reaction was 
carried out in ethanol at 60°C using Vazo-52 as an initiator and 
polyvinylpyrrolidone (PVP) as a surfactant.  For the analogous polymers, 
the same reaction scheme was used, but without the addition of the (1,5-
N-vinylformamido) ethyl ether crosslinker or the PVP surfactant. 
 
The reagent mixture was then sparged with argon for 10 minutes to 
remove dissolved oxygen, then heated in a silicone oil bath to 60°C and 
stirred at approximately 900 RPM.  The reaction was carried out 
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isothermally under an argon atmosphere for 24 hours.  The product was 
then dialyzed against deionized water using a 1 kDa MWCO regenerated 
cellulose ester dialysis tube (Spectrum Laboratories, Inc., Rancho 
Dominquez, CA) for 24 hours.  The dialysate was changed at least 5 times 
to ensure complete solvent exchange.  Linear polymers were synthesized 
analogously, but without the addition of (1,5,-N-vinylformamido) ethyl ether 
crosslinker or PVP surfactant.  Particles were then further purified by 
centrifugation for 1 hour at 18,000 rpm.  Each centrifugation cycle was 
repeated at least 3 times. 
For the hydrolysis step, particle and polymer suspensions were 
flash-frozen in liquid nitrogen and then lyophilized.  Samples were 
resuspended in 1 M NaOH(aq) and sonicated for 1 hour at ambient 
temperature, as described previously.59  The pH of each solution was then 
titrated to approximately 7 using 1 M HCl(aq), and the suspensions were 
dialyzed against deionized water (MWCO 100 Da) for at least 24 hours to 
remove salt and hydrolysis byproducts.  Dialysate was changed at least 3 
times.  The hydrolyzed particles and polymers were then flash-frozen in 
liquid nitrogen and lyophilized prior to analysis with FTIR. 
 
Neutron Scattering:  SANS experiments were carried out on the NG7 30 m 
SANS instrument at the NIST Center for Neutron Research (NCNR) in 
 46
Gaithersburg, MD.  Neutrons of wavelength λ = 6 Å with a distribution of 
∆λ/λ = 10 % were incident on samples held in quartz cells.  Three different 
sample to detector distances were used to give an overall q range of 
0.0038 Å < q < 0.37 Å, where q = (4π/λ)sin(θ/2) is the magnitude of the 
scattering vector.  Sample scattering was corrected for background and 
empty cell scattering, and the sensitivities of individual detector elements 
were normalized.  The corrected data sets were circularly averaged and 
placed on an absolute scale using software supplied by the NCNR.69 
USANS experiments were carried out on the BT54 perfect crystal 
diffractometer (PCD) at the NCNR using the same samples described 
above.  The overall q range was 3.8 x 10-5 Å < q < 0.002 Å.  All data were 
reduced and analyzed using software provided by the NCNR.69  Here, only 
slit-smeared data are shown. 
Samples for all neutron scattering experiments were prepared 
using D2O as a solvent, thus the scattering length density of the solvent 
was 6.3 x 10-6 Å-2.  Particle densities were approximated using a weighted 
average of the neat monomer densities.  Scattering length densities of the 
particles were calculated using the NCNR scattering length density 
calculator70 with atomic scattering lengths obtained from V.F. Sears.71 
 
TEM Imaging: TEM images were acquired on a Philips CM300FEG TEM 
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(Cs = 1.2 mm) operated at 300 kV using a 10.8 mrad objective aperture 
semiangle.  Samples were drop-mounted onto silicon-supported 25 nm 
thermal SiO2 membranes (Dune Sciences NG01-011A) and allowed to dry 
in air for 24 hours before imaging.    Samples were imaged using a Gatan 
GIF-200 in energy filtered mode using a 10 eV acceptance slit.  To 
increase signal to noise ratios, the images were constructed from a series 
of 100, 0.5 second exposures, which were then aligned and summed to 
produce the final image. 
 
Fourier Transform Infrared Spectroscopy: FTIR was used to determine the 
effects of hydrolysis on the functional groups present within the 
nanoparticles (Smiths Illuminate FTIR Microscope).  After lyophilization, 
hydrolyzed and non-hydrolyzed samples were resuspended in deionized 
water by sonicating in an ultrasonication bath for one hour.  Particle and 
polymer suspensions were then decanted onto a gold-plated microscope 
slide and allowed to dry at ambient conditions under a chemical hood.  
FTIR spectra were then collected from the resultant polymer and particle 
films.  All experiments were conducted on a diamond attenuated total 
reflectance objective microscope accessory.  Reported spectra are the 
average of 128 scans. 
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19F-NMR Spectroscopy:  19F spectra were acquired on a Bruker DRX 400 
MHz NMR equipped with a QNP probe at The University of Kansas.  The 
samples were suspended in D2O and the spectrometer was locked to this 
solvent during the experiments.   All samples were recorded with a sweep 
width of 99 ppm, a transmitter offset of -80 ppm and a 1 second delay.  
Spectra were collected with 16 scans on the particles synthesized with the 
1H,H-perfluoro-n-octyl acrylate monomer and 64 scans were used for the 
particles synthesized using the 2-(allyl)hexafluoroisopropanol monomer. 
 
3.3 Results 
Small Angle Neutron Scattering: Fluorinated nanoparticles were prepared 
using a method similar to one described previously.68  After purification, 
samples were suspended in D2O and analyzed using SANS and USANS 
at several different concentrations.  The scattering length density values 
for particles prepared with each of the fluorinated monomers are given in 
Table 3.1. 
 
Table 3.1: Scattering Length Densities of Fluorinated Nanoparticles 
Monomer Estimated Particle Density (g/cm3) Scattering Length Density (Å
-2) 
1H,1H-perfluoro-n-
octyl acrylate 1.30 3.00 x 10
-6
 
2-Allyl 
hexafluoroisopropanol 1.15 2.73 x 10
-6
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Non-linear least-squares model fitting was performed using Schulz-
distributed spheres of uniform scattering length density, given by the 
normalized Schulz distribution: 
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where Ravg is the mean radius of the particles, and x = R/Ravg, z is a 
function of the polydispersity, p = σ/Ravg, and z = 1/p2 – 1, σ is the 
standard deviation of the distribution, and Γ(z+1) is the gamma function.   
For a typical SANS experiment, the SANS intensity is given by: 
( ) ( ) ( ) bqSqPVqI p +∆= 2ρφ  
where φ is the particle volume fraction, Vp is the particle volume, ∆ρ is the 
difference between the scattering length density of the particles and the 
scattering length density of the solvent (ρp - ρs), and b is the incoherent 
background scattering intensity.  The function P(q) is the intraparticle form 
factor averaged over the Schulz distribution, and S(q) is the interparticle 
interference factor, which is equal to 1 in the case of non-interacting 
particles.  The particles were confirmed to be non-interacting by 
measuring at several dilutions.  Combining this equation with the 
normalized Schulz distribution yields: 
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where, <V> is the average volume of a particle.  The function F is the 
scattering amplitude of a sphere, and is given by: 
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The average volume, <V>, is calculated using the 3rd moment of R and is 
given by: 
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For the particles prepared using the 1H,1H-perfluoro-n-octyl acrylate 
monomer, the USANS data were initially fit to obtain the size and 
polydispersity of the particles.  For the smaller concentrations 
(concentrations less than 1 mg/mL), the polydispersity was held at the 
value calculated from the most concentrated sample.  The SANS data 
were also fit using the parameters calculated from the USANS data, 
although the background and the volume fraction parameters were 
relaxed.  The model was then fit to both the USANS and the SANS data 
simultaneously to optimize the fit.  The spectra are shown in Figure 3.2, 
and the model parameters are listed in Table 3.2.  The model suggests 
that the particles are between 390.1 nm ± 4.4 nm and 413.1 nm ± 2.6 nm 
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in diameter with a polydispersity of 0.5218.  The discrepancies between 
the volume fractions calculated for the USANS and SANS data for each 
concentration could be due to small amounts of separation that occurred 
while the samples were waiting for analysis on the SANS instrument. 
 
 
 
Figure 3.2: USANS and SANS spectra of particles prepared with 1H,1H-
perfluoro-n-octyl acrylate monomer.  Particles were dispersed in D2O 
without surfactant at various concentrations.  Data were fit using a Schulz 
sphere analytical model.  The model suggests that the particles are 
between 290 and 414 nm in diameter with a polydispersity of 
approximately 0.52. 
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 For the 2-(allyl)hexafluoroisopropanol monomer, only spectra 
obtained for concentrations of 1 mg/mL and 0.5 mg/mL were analyzed due 
to insufficient scattering at lower concentrations.  Only the USANS spectra 
were used in the analysis of 2-(allyl)hexafluoroisopropanol because the 
SANS data were too noisy and the expected particle size was within the 
range suitable for USANS measurements.  The model was fit to each data 
set individually, and then to both concentrations simultaneously while 
holding the polydispersity from the highest concentrated sample constant 
to minimize the degrees of freedom and to ensure a consistent fit with 
both data sets.  In the spectra for the particles prepared with the 2-
Table 3.2: Model parameters for nanoparticles prepared with 1H,1H-
perfluoro-n-octyl acrylate monomer 
 1 mg/mL 0.5 mg/mL 
Parameter SANS USANS SANS USANS 
Volume Fraction 2.99 x 10
-3
 
± 2.8 x 10-5 
1.32 x 10-3 
± 1.4 x 10-5 
1.30 x 10-3 
± 1.3 x 10-5 
3.54 x 10-4 ± 4.1 x 
10-6 
Mean Diameter (nm) 413.1 ± 2.6 410.6 ± 2.8 
Polydispersity 0.522 0.522 
Background (cm-1 sr-1) 0.071 0.057 
   
 0.2 mg/mL 0.1 mg/mL 
Parameter SANS USANS SANS USANS 
Volume Fraction 5.92 x 10
-4
 
± 6.5 x 10-6 
1.41 x 10-4 
± 1.9 x 10-6 
2.88 x 10-4 
± 4.8 x 10-6 
6.03 x 10-5 ± 1.1 x 
10-6 
Mean Diameter (nm) 399.1 ± 3.0 390.1 ± 4.4 
Polydispersity 0.522 0.522 
Background (cm-1 sr-1) 0.056 0.059 
Error is equal to 1 standard deviation of the fitted value.  Values without reported error 
were held exact during model convergence. 
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(allyl)hexafluoroisopropanol monomer, the data were too noisy to 
accurately determine both the particle size and the polydispersity, so the 
polydispersity was held at 0.5, which is close to the value obtained for the 
particles prepared with the 1H,H-perfluoro-n-octyl acrylate monomer.  The 
spectra for these particles are shown in Figure 3.3, and the model 
parameters are listed in Table 3.1.  The model suggests an average 
particle size of 281.2 nm ± 16.4 nm. 
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Figure 3.3: USANS spectra of particles prepared with 2-
(allyl)hexafluoroisopropanol monomer.  Particles were dispersed in D2O 
without surfactant at concentrations of 1 mg/mL and 0.5 mg/mL.  Data 
were fit using a Schulz sphere analytical model.  The model suggests that 
the particles are approximately 282 nm in diameter.  The polydispersity 
was held to 0.5 due to the noisiness of the data. 
 
Table 3.3: Model parameters for nanoparticles prepared with 2-allyl 
hexafluoroisopropanol monomer 
Parameter 1 mg/mL 0.5 mg/mL 
Volume Fraction 1.62 x 10-3 ± 1.5 x 10-4 6.56 x 10-4 ± 6.2 x 10-5 
Mean Diameter (nm) 281.2 ± 16.4 
Polydispersity 0.5 
Background (cm-1 sr-1) 0.218 
Error is equal to 1 standard deviation of the fitted value.  Values without reported error 
were held exact during model convergence. 
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Transmission Electron Microscopy: The sizes of the fluorinated 
nanoparticles were further corroborated by the TEM images (Figure 4), 
which show particles prepared with the1H,H-perfluoro-n-octyl acrylate 
monomer (Panel A) that are less than 400 nm in diameter.  Panel B shows 
particles prepared with the 2-(allyl)hexafluoroisopropanol monomer that 
are less than 500 nm in diameter.  The observed particle sizes corroborate 
the neutron scattering data.  This suggests that the particles might be 
useful as a passive targeting agent for tumor imaging. 
 
Figure 3.4: TEM Image of particles prepared with 1H,H-perfluoro-n-octyl 
acrylate monomer (A) and 2-(allyl)hexafluoroisopropanol  monomer (B). 
 
Fourier Transform Infrared Spectroscopy: Nanoparticles were analyzed 
using FTIR to determine the suitability of the particles for chemical 
modification and conjugation strategies.  Analogous polymers prepared 
without the (1,5-N-vinylformamido) ethyl ether crosslinker or the PVP 
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surfactant were also analyzed as a comparison.  The ability to hydrolyze 
the amide to an amine could enable one to conjugate a carboxyl 
terminated targeting ligand to the particles or polymers to facilitate active 
targeting of pathological tissue.  This can be done with simple chemistry 
that is well described in the literature.20, 72  Particles prepared using the 
1H,H-perfluoro-n-octyl acrylate monomer (Figure 3.5, Panel A) showed 
evidence of hydrolysis of both the formamide group and of the 
perfluorinated ester. 
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Figure 3.5: FTIR spectra of fluorinated nanoparticles.  (A) Shows particles 
and (B) shows polymer prepared with 1H,1H-perfluoro-n-octyl acrylate 
monomer.  (C) Shows particles and (D) shows polymer prepared with the 
2-(allyl)hexafluoroisopropanol monomer.  All solutions were allowed to 
evaporate prior to analysis of the resultant nanoparticle or polymer film. 
 
Hydrolyzed particles showed a strong peak at 3326 cm-1, which is within 
the hydrogen bonded OH region (3300 – 2500 cm-1) and the primary 
aliphatic amine region (3450 – 3250 cm-1).  The emergence of the OH 
frequency was due to the hydrolysis of the perfluorinated acrylate (1H,H-
perfluoro-n-octyl acrylate), which was hydrolyzed to a carboxylic acid.  
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Although the presence of an amine after hydrolysis suggests that the 
particles can be bound to a targeting ligand using simple chemistry, the 
fact that the fluorinated ester was hydrolyzed indicates that particles 
prepared with the 1H,H-perfluoro-n-octyl acrylate monomer would not be 
suitable for use as an active targeting agent if conversion to the primary 
amine is necessary.  There was no evidence of ether hydrolysis. 
The non-hydrolyzed particles prepared with the 1H,H-perfluoro-n-
octyl acrylate showed a peak at 1753 cm-1 suggesting a carbonyl ester 
(1750 – 1725 cm-1) and an amide I carbonyl peak (1670 – 1650 cm-1), 
both of which were absent in the hydrolyzed particles’ spectrum.  The 
hydrolyzed particles also showed an N-H deformation peak at 1548 cm-1, 
which is near the typical region (1650 – 1580 cm-1) but was likely shifted to 
higher frequency due to hydrogen bonding.  This would indicate the 
presence of an amine.  Representative structures of the non-hydrolyzed 
and hydrolyzed particles are shown in Figure 3.6. 
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Figure 3.6: Representative chemical structures of non-hydrolyzed and 
hydrolyzed particles prepared using the different monomers. (A) 
Hydrolysis of particles prepared using the 1H,1H-perfluoro-n-octyl acrylate 
monomer, where amide groups were hydrolyzed to their corresponding 
amines, and the fluorinated ester was also cleaved.  (B) Hydrolysis of 
particles prepared using the 2-(allyl)hexafluoroisopropanol monomer, 
where the amide groups were converted to primary and secondary 
amines, while the fluorinated regions remained intact. 
 
The analogous polymer samples (Figure 3.5, Panel B) synthesized 
with the 1H,H-perfluoro-n-octyl acrylate monomer showed much evidence 
of hydrolysis.  The hydrolyzed polymer spectrum showed a broad peak 
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around 3300 cm-1, which is indicative of both OH stretching (3300 – 2500 
cm-1) and primary amines (3450 – 3250 cm-1).  The non-hydrolyzed 
spectrum showed small peaks at 1749 cm-1 and 1669 cm-1, both of which 
were absent in the hydrolyzed spectrum and indicated the presence of a 
carbonyl ester (1750 – 1725 cm-1) and an amide I (carbonyl) peak (1670 – 
1650 cm-1), respectively.  Additionally, two peaks at 1196 cm-1 and 1140 
cm-1 were present in the non-hydrolyzed spectrum, and indicated the 
presence of an ester C-O stretch.  These peaks were very obviously 
absent in the hydrolyzed spectrum, which suggested the hydrolysis of the 
fluorinated ester group. 
 Nanoparticles prepared using the 2-(allyl)hexafluoroisopropanol 
monomer (Figure 3.5, Panel C) qualitatively suggested hydrolysis of the 
formamide group on the N-vinylformamide monomer and the (1,5-N-
vinylformamido) ethyl ether crosslinker.  The non-hydrolyzed spectrum 
showed a peak at 3401 cm-1, which is within the OH stretch region (3300 – 
2500 cm-1).  Unfortunately, this overlaped with the primary amine region 
(3450 – 3250 cm-1), making it difficult to distinguish the two.  The 
hydrolyzed particles showed a broad peak at 3378 cm-1.  Because this 
frequency is shifted toward the primary amine region and is at higher 
intensity, it stands to reason that this peak was due to influence from both 
the hydroxyl group on the 2-(allyl)hexafluoroisopropanol monomer and the 
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primary amine from the hydrolyzed formamide groups.  Additionally, both 
spectra showed peaks at 1648 cm-1, which suggested the presence of a 
hydrogen-bonded carbonyl group.  This is most likely from the formamide 
group (amide I), which was present in the non-hydrolyzed particles and 
was likely present within the hydrolyzed particles to some degree, possibly 
buried within the particles where they might be sterically shielded from 
hydrolysis.  The high intensity of this peak is not observed in the linear 
hydrolyzed polymer, which suggested that the crosslinking may have 
buried some of the formamide groups within the particles.  The presence 
of an amine after hydrolysis suggested that these particles could be 
successfully conjugated with a carboxyl terminated targeting ligand.  
Representative structures of the hydrolyzed and non-hydrolyzed particles 
are shown in Figure 3.6.  Like in the previous sample, there was no 
evidence of ether hydrolysis. 
 The spectra for the analogous polymer samples (Figure 3.5, Panel 
D) show evidence of formamide hydrolysis.  Like the particles, both the 
hydrolyzed and non-hydrolyzed polymers show peaks in the OH stretch 
region (3300 – 2500 cm-1), which is expected from to the 2-
(allyl)hexafluoroisopropanol monomer.  This region overlaps with the 
primary aliphatic amine region (3450 – 3250 cm-1) and is more intense for 
the hydrolyzed polymer, suggesting that this peak is influenced by both 
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the hydroxyl group and the primary amine.  Additional evidence for 
hydrolysis is the decrease in the intensity of the carbonyl peak (1650 cm-
1), which is likely shifted to a higher frequency in both spectra due to 
hydrogen bonding.  The lower intensity of this peak in the hydrolyzed 
sample could indicate the loss of the formamide group, which would be 
expected.  The fact that this peak did not diminish in intensity in the 
particles could be due to the crosslinking, which might bury formamide 
groups within the particles, again rendering them sterically isolated from 
hydrolysis. 
 
19F NMR Spectroscopy: Nanoparticle samples were analyzed using 19F-
NMR to determine their potential as 19F-MRI contrast agents.  Figure 3.7 
shows the 19F-NMR spectra of the fluorinated nanoparticles. 
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Figure 3.7: 19F-NMR spectra of fluorinated nanoparticles.  (A) The 
spectrum for nanoparticles prepared using the 1H,1H-perfluoro-n-octyl 
acrylate monomer, which showed a broad peak at -83.35 ppm.  (B) The 
spectrum for nanoparticles prepared using the 2-
(allyl)hexafluoroisopropanol monomer, which showed a sharp peak at -
76.21 ppm.  Insets show the spectra for the entire sweep width. 
 
 
Particles prepared with the 1H,H-perfluoro-n-octyl acrylate monomer 
showed a peak between -83 ppm and -84 ppm (Figure 3.7, Panel A).  This 
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peak is from the CF2 group closest to the oxygen atom.  Additionally, the 
spectrum shows an out-of-phase signal near -121 ppm (inset), which is 
from the perfluorinated region (-CF2CF2-) of the pendant group.  Particles 
prepared with the 2-(allyl)hexafluoroisopropanol monomer show a peak 
around -76 ppm (Figure 3.7, Panel B).  This peak is similar to the CF2 
peak from the 1H,H-perfluoro-n-octyl acrylate particles because both have 
the same proximity to a nearby oxygen atom.  Both particles exhibit fairly 
narrow widths in their 19F-NMR spectra, suggesting that some fluorinated 
groups are well solvated with a degree of mobility.  This suggests that the 
particles would produce a signal in 19F-MRI and would therefore be 
suitable for use as a 19F-MRI contrast agent.27 
 
3.4 Discussion 
Current studies in the area of 19F MRI contrast agents have validated the 
premise of developing colloidally stable, fluorinated contrast agents using 
nanoemulsions that contain a liquid perfluorocarbon phase.  These studies 
have investigated fluorinated liquids such as perfluoro-15-crown-5-ether 
and perfluorooctyl bromide, which were emulsified into an aqueous phase 
using an appropriate biocompatible surfactant.46, 47, 49, 51  Other studies 
have created novel fluorinated amphiphilic block copolymers that formed 
micelles in water, typically using a living free radical polymerization 
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method.12, 27, 32, 33  In a previous study, the idea of synthesizing fluorinated 
nanoparticles using a single step, free radical polymerization technique 
was validated.68  In this study, fluorinated nanoparticles were prepared 
using a free radical polymerization method that contained a hydrophilic 
monomer, a hydrophilic crosslinker, and one of two fluorinated monomers.  
Future studies will continue to optimize the reaction method to produce 
particles of smaller size by better controlling the reaction rate to 
encourage the formation of smaller molecular weight polymers, which 
could lead to smaller particles.  After synthesis, the particles were 
evaluated for their suitability as a 19F MRI contrast agent that can be 
targeted to specific pathological sites (e.g. tumors, atherosclerosis) using 
either active or passive targeting strategies.   
A potential passive targeting strategy that has been investigated as 
a means to deliver antineoplastic agents to tumors exploits the anatomical 
and physiological abnormalities of tumor vasculature.64  Typically, the 
blood vessels in tumor tissue are tortuous, poorly organized and contain 
numerous pores due to large gap junctions between endothelial cells, 
which can compromise lymphatic drainage.63-67  These anatomical 
aberrations can cause extensive leakage of macromolecular agents and 
small nanoparticles from the capillaries into the tumor interstitium, where 
they can accumulate.64  This phenomenon is called the enhanced 
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permeability and retention effect (EPR effect), and has been studied using 
macromolecular therapeutic agents.73, 74  It has also been observed with 
polymeric nanoparticles that are several hundred nanometers in 
diameter.75  Neutron scattering measurements and TEM images indicate 
that the particles prepared in this study are between approximately 200 
nm and 400 nm in diameter, suggesting that they might be too large for 
passive targeting strategies. 
Additionally, active targeting strategies using ligands that 
specifically bind selected tumor targets may amplify the specificity of 
nanoparticles.62, 63  For example, amine-functionalized nanoparticles will 
react with ligands terminated with succinimide esters or isothiocyanates.76  
Carboxylated nanoparticles or ligands can be made reactive toward 
amine-terminated moieties using 1-ethyl-3-
(dimethylaminopropyl)carbodiimide (EDC) and either N-
hydroxysuccinimide (NHS) or N-hydroxysulfosuccinimide (sulfo-NHS) to 
form an amine-reactive succinimide ester.76  FTIR spectra suggested that 
formamide groups on the surface of nanoparticles and linear polymers 
prepared in this study using the 2-(allyl)hexafluoroisopropanol fluorinated 
monomer can be hydrolyzed at high pH to liberate amine groups, yielding 
reactive sites for ligand conjugation to facilitate active targeting strategies.  
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Future studies will evaluate the reactivity of the amines and the amides to 
determine the most effective conjugation strategy for active targeting. 
 In addition to tumor imaging, another potential clinical application 
for nanoparticle-based MRI contrast agents is atherosclerosis imaging.  
This technique could prove useful in identifying patients at high-risk for 
myocardial infarction who have not been identified by routine clinical 
evaluation, and may also be useful in characterizing the vulnerability of 
atheroma present in high-risk areas of the coronary vasculature.77  As an 
active targeting technique, nanoparticles could be conjugated with a ligand 
that would facilitate binding to proinflammatory adhesion molecules 
expressed during atherogenesis.  Possible targets include intercellular 
cell-adhesion molecule-1 (ICAM-1) and vascular cell-adhesion molecule-1 
(VCAM-1), both of which are overexpressed on the endothelium around 
atherosclerotic lesions.77-79  Studies have also developed paramagnetic 
MRI contrast agents that actively target thrombus,54, 80 and paramagnetic 
contrast agents have been designed to target integrins associated with 
angiogenesis because of the high vascularity of atherosclerotic lesions 
compared to normal vessel tissues.81  Another study targeted 
macrophages, which are key effector inflammatory cells in 
atherosclerosis.82  Analogous methods of targeting atheroma using 
ultrasound contrast agents have also been demonstrated.79   
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Although the linear polymers synthesized in this study were used 
only as a control, they could have diagnostic applications that should be 
evaluated in the future.  For example, linear polymers synthesized from 
the 2-(allyl)hexafluoroisopropanol and N-vinylformamide monomers lacked 
visual turbidity in water, but presumably formed micelles approximately 
200 nm in diameter, as estimated by dynamic light scattering 
measurements.  The reactivity of the amide and amine groups (post 
hydrolysis) could facilitate conjugation with targeting ligands for active 
targeting strategies.  Future studies will examine the possibility of using 
these fluorinated monomers as 19F MRI contrast agents, and further 
examine the suitability of the crosslinked nanoparticles for use in vivo. 
 
3.5 Conclusions 
This work has aimed to further develop the use of fluorinated 
nanoparticles as 19F MRI contrast agents.  The results of this study 
suggested that fluorinated nanoparticles prepared using a simple free 
radical polymerization technique would produce a sufficient magnetic 
resonance signal for 19F-MRI.  Nanoparticles may be useful for passive 
targeting strategies that rely on phenomena such as the enhanced 
permeability and retention (EPR) effect, as well as active targeting 
strategies that rely on targeting ligands to amplify nanoparticle uptake into 
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pathological tissue, such as tumor tissue or atherosclerotic lesions.  The 
results suggested that nanoparticles or polymers prepared using the 2-
(allyl)hexafluoroisopropanol fluorinated monomer may be hydrolyzed to 
liberate free amines for possible conjugation with targeting ligands.  
Fluorinated imaging agents may ultimately prove to be safer and more 
effective than currently available paramagnetic contrast agents, such as 
gadolinium chelates, due to the demonstrated biocompatibility of 
fluorinated compounds.  Future studies will examine the uptake of ligand-
conjugated nanoparticles in in vitro cell culture, as well as the in vivo 
efficacy of fluorinated nanoparticles as 19F-MRI contrast media. 
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Chapter 4 
Fluorinated-Fluorescent Nanoparticles as in vitro Imaging 
Agents for Optical Fluorescence Imaging and Secondary 
Ion Mass Spectrometry (SIMS) Imaging 
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4.1 Introduction 
Nanoparticles possess unique physical and chemical properties that make 
them useful for a variety of biomedical applications, including drug delivery 
and biomedical imaging.  Several studies have utilized nanoparticles for a 
variety of in vitro and in vivo biomedical imaging techniques, including 
magnetic resonance imaging (MRI),27, 31, 68 positron emission tomography 
(PET),20 computed tomography (CT),83 and optical fluorescence 
imaging.84  In addition, nanoparticles can serve as a core platform for the 
integration of several functional moieties to facilitate synergistic imaging 
using multiple techniques.85  For example, paramagnetic nanoparticles 
have been conjugated with radionuclides to facilitate integrated MRI and 
PET imaging, providing better spatial resolution and improved signal 
sensitivity.86  Additionally, nanoparticles have been used to couple PET 
imaging with fluorescence imaging,30 and paramagnetic nanoparticles 
have been integrated with fluorescent molecules to enable integrated MRI 
and optical fluorescence imaging.87 
 Mass spectrometry techniques, such as secondary ion mass 
spectrometry (SIMS) and matrix-assisted laser desorption/ionization 
(MALDI), are gaining recognition as high resolution in vitro biomedical 
imaging techniques.15, 37, 44, 88  In SIMS imaging, a sample is bombarded 
with an electrostatically-focused primary ion beam, causing secondary 
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ions to be ejected from the surface, which are collected by a mass 
spectrometer (Figure 4.1).16 
 
Figure 4.1: SIMS imaging of a cell sample.  The sample is raster scanned 
by a primary ion beam, which causes secondary ions to be desorbed from 
the surface and collected by a mass spectrometer.  The mass spectral 
data can then be compiled to generate a false-color image of the sample 
surface that is representative of the composition at each pixel. 
 
As the primary ion beam is raster scanned across the surface of the 
sample, a mass spectrum can be obtained for each pixel, enabling the 
generation of images that are representative of the spatial distribution of 
specific ions desorbed from the sample surface.13  SIMS has been used 
successfully for cellular and histological imaging,88 and as a means to 
measure radiopharmaceutical distributions within cells.89  SIMS imaging 
has also been used to measure natural isotopic ratios of carbon and 
nitrogen in cultured cells.90  Additionally, SIMS has applications in the 
pharmacological evaluation of fluorinated drugs, like 5-fluorouracil, due to 
fluorine’s biological rarity and high ion yield in SIMS.88 
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 Multimodal imaging probes are quickly becoming important tools for 
advanced clinical diagnostics.85  One way to mediate the specificity of an 
imaging probe to the site of interest is through active targeting 
mechanisms, such as conjugating an antibody or targeting ligand to the 
surface of the particle to facilitate binding to a cell surface antigen of 
interest.  The LABL peptide (ITDGEATDSG) has been derived from 
leukocyte function associated antigen-1 (LFA-1) for this purpose.  LFA-1 
binds to intercellular adhesion molecule-1 (ICAM-1) on the surface of 
epithelial cells to facilitate leukocyte recruitment and extravasation to sites 
of inflammation.78, 91  The LABL peptide has been shown to enhance 
nanoparticle uptake to ICAM-1 expressing cells when conjugated to the 
surface of drug-loaded nanoparticles.72  By analogy, it should prove to be 
an effective means to target ICAM-1 expressing cells with multimodal 
nanoparticle imaging probes for in vitro imaging. 
In this study, fluorinated-fluorescent nanoparticles were 
synthesized and evaluated as a potential multimodal in vitro imaging 
probe for optical fluorescence and SIMS imaging (Figure 4.2). 
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Figure 4.2: Synthesis of fluorinated-fluorescent nanoparticles.  For each 
batch, monomers were dissolved in ethanol containing 
polyvinylpyrrolidone (PVP) as a surfactant and Vazo-52 initiator.  The 
reaction was carried out at 60ºC for 24 hours. 
 
Fluorine was selected as a SIMS imaging medium because of its 
biological rarity and high ion yield in SIMS.16  Particles were conjugated 
with LABL peptide using an oxime formation strategy described previously 
that utilizes an aminooxy derivative of the LABL peptide to bind to 
formamide groups on the particles’ surface (unpublished data) (Figure 
4.3). 
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Figure 4.3: Proposed conjugation mechanism by oxime formation.  The 
aminooxy group from the aminooxy-terminated LABL peptide attacks the 
carbonyl carbon of a formamide group on the surface of the particles.  
This induces the formation of a water leaving group, and the formation of 
an aldoxime-analog. 
 
Other methods of using aminooxy derivatives to form oxime conjugates 
have been previously described.92-94  Binding and internalization of 
conjugated nanoparticles in ICAM-1 expressing human umbilical cord 
vascular endothelial cells (HUVECs) was demonstrated using 
fluorescence imaging.  The study suggests that these particles may be a 
useful probe for bimodal imaging using optical fluorescence and SIMS. 
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4.2 Materials and Methods 
Materials: All materials were purchased from Sigma-Aldrich unless 
otherwise stated. 1H,H-perfluoro-n-octyl acrylate was purchased from 
ExFluor Research Corporation (Round Rock, TX).  (E)-2,2’-(diazine-1,2-
diyl)bis(2,4-dimethylpentanenitrile) (Vazo-52) was purchased from DuPont 
(Wilmington, DE).  Dialysis membranes were purchased from Spectrum 
Labs (Rancho Dominquez, CA).  Prior to nanoparticle synthesis, (1,5-N-
vinylformamido) ethyl ether was synthesized as previously described.59, 60  
Impurities were precipitated out of N-vinylformamide using absolute 
ethanol and vacuum filtered prior to use.  All other reagents were used as 
received. 
 
Fluorinated-Fluorescent Nanoparticle Synthesis: Nanoparticles (NPs) 
were synthesized using a free radical polymerization method similar to 
one described previously.68  First, 20 µL of 1H,H-perfluoro-n-octyl acrylate, 
20 µL of (1,5-N-vinylformamido) ethyl ether and 20 µL of N-vinyl 
formamide were dissolved in absolute ethanol containing 0.015 g/mL 
polyvinylpyrrolidone (PVP) as a surfactant (MW approximately 360 kDa).  
Next, 0.0055 mg of fluorescein-o-acrylate and 0.0076 mg of Vazo-52 
initiator were added to the solution under stirring.  The reagent mixture 
was sparged with nitrogen for 10 minutes to remove dissolved oxygen, 
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then was heated in a silicone oil bath to 60°C and stirred.  The reaction 
was carried out isothermally under a nitrogen atmosphere for 24 hours.  
The reaction vessel was protected from ambient light to minimize 
photobleaching of the fluorescent monomer.  The product was then 
dialyzed against deionized water using a 500 Da MWCO regenerated 
cellulose ester dialysis tube for 24 hours.  The dialysate was changed at 
least 5 times to ensure complete solvent exchange and the removal of 
unreacted fluorescein-o-acrylate monomer.  The resultant nanoparticle 
suspension was then purified by centrifugation for 1 hour at 18,000 rpm.  
Each centrifugation cycle was repeated at least 3 times.  Particles were 
then flash-frozen in liquid nitrogen and lyophilized.  After lyophilization, 
resuspended particle sizes and zeta potentials were measured using 
dynamic light scattering. 
 
Aminooxylated LABL Peptide Synthesis: Aminooxy peptides were 
synthesized using 9-fluorenylmethyloxycarbonyl-protected amino acid 
chemistry on polyethylene glycol-polystyrene resins.  The peptides 
synthesized where aminooxy LABL (aminooxy-ITDGEATDSG), an ICAM-1 
antagonist.  Peptides were deprotected, cleaved from resin, and isolated 
by precipitation in ether.  Purification was completed using preparatory 
high performance liquid chromatography (HPLC), followed by 
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lyophilization.  Peptide identity was verified and purity/content was 
assessed using analytical HPLC and mass spectroscopy. 
 
Conjugation of Aminooxylated LABL Peptide to NPs: For the conjugation 
step, 5.9 mg of nanoparticles were re-suspended in 5.9 mL of 20 mM 
acetate buffer, to a final concentration of 1 mg/mL.  Particles were then 
sonicated for 10 minutes to disperse the suspension.  A volume of 3 mL 
(approximately 3 mg of nanoparticles) was transferred to a separate 
reaction flask, to which 21.43 mg of aminooxy-LABL (aminooxy-
ITDGEATDSG) was added and dissolved by stirring.  The pH of both the 
nanoparticle (NP) solution and LABL-conjugated NP solution (LABL-NPs) 
was measured and adjusted to pH 5.5.  Reaction flasks were stirred at 
500 RPM for 16 hours.  Reaction time was based on previously conducted 
studies (unpublished data).  After the reaction, the solution was 
extensively dialyzed against deionized H2O (MWCO 3500 Da) to remove 
unreacted peptide, followed by lyophilization of the dialyzed product.  
Conjugation efficiency was measured using HPLC. 
 
Up-regulation of ICAM-1 by Tumor Necrosis Factor-α: HUVECs (4.5 x 105 
cells in 80 µl of serum free F12K medium) were stimulated using 1,000 
U/ml of Tumor Necrosis Factor- α (TNF-α) for 24 hrs.  Cells at the same 
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concentration were not activated and used as a control.  HUVECs, with or 
without ICAM-1 upregulation, were incubated with 5% BSA in PBS for 10 
min at 4 °C and then anti-ICAM-1-FITC (0.05 mg/ml) was added to cells 
and incubated at 4 ºC for 45 min.  Free antibodies were removed by 
rinsing three times with PBS after centrifugation (4,000 RPM, 3 min).  The 
fluorescence intensity of the cells was analyzed by flow cytometry.  Data 
analysis was performed using Cell Quest software (BD). 
 
Binding and Uptake of LABL-NPs by HUVECs: The binding and uptake of 
LABL-NPs was studied using fluorescence spectroscopy.  TNF-α 
stimulated HUVECs (5 x 105 cells/ml) were added to a 96 well-plate (100 
µl/well) and incubated with LABL-NPs or NPs (3.7 mg/ml, 30 µl) at 37 °C 
for 5, 15, 30 and 60 min and washed with PBS.  The fluorescence 
intensity of cells was measured using a fluorescence plate reader 
(Spectramax M5; ex., 450 nm; em., 500 nm). 
 
Fluorescence Microscopy of the Uptake of LABL-NPs by HUVECs: 
Fluorescence microscopy was used to compare the extent of binding and 
uptake of LABL-NPs and unconjugated NPs in HUVECs.  HUVECs (2.5 x 
105 cells/ml) were activated by using 1,000 U/ml TNF-α for 24 hrs.  Cells 
were then added to an 8-well plate. LABL-NPs or unconjugated 
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fluorescent NPs (2.5 mg/ml) were incubated with the cells for 5, 15, 30 min 
and 1 hr at 37°C, 5% CO2.  Unbound nanoparticles were removed by 
washing three times with PBS and fixed with 4% paraformaldehyde.  
Nuclei were labeled with DAPI dilactate (blue) (300 nM, ex: 358 nm, em: 
461 nm) for 5 min at 37ºC, 5% CO2.  Fluorescence micrographs were 
acquired using the UV and FITC filter sets of a Nikon Eclipse 80i 
microscope equipped for epifluorescence.  Micrographs were captured 
using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) and 
analyzed by Metamorph, version 6.2 (Universal Imaging Corp., West 
Chester, PA). 
 
Lysosomal Trafficking of LABL-NPs in HUVECs: Fluorescence microscopy 
was utilized to investigate the intracellular fate of LABL-NPs and 
untargeted NPs in HUVECs.  HUVECs (2.5 x 105 cells/ml) were activated 
with 1,000 U/ml of TNF-α for 24 hrs.  Cells were incubated with Texas red 
dextran (Mw 10,000, lysine fixable, 1 mg/ml) for 2 hours at 37°C, 5% CO2 
and washed three times with PBS.  Cells were then incubated in serum 
free media at 37°C, 5% CO2 for 12 hrs to allow the dye to reach the 
lysosomes.  Afterward, LABL-NPs or unconjugated NPs (200 µl, 2.5 
mg/ml) were added to cells and incubated for 5, 15, 30 and 60 min at 
37°C, 5% CO2.  Unbound nanoparticles were removed by washing three 
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times with PBS.  Nuclei were labeled with DAPI dilactate (blue) (300 nM, 
ex: 358 nm, em: 461 nm) for 5 min at 37ºC, 5% CO2.  Cells were then 
fixed with 4% paraformaldehyde.  Fluorescence emissions of 
nanoparticles and lysosomes were observed using FITC and rhodamine 
filter sets, respectively (Nikon Eclipse 80i microscope equipped for 
epifluorescence).  Micrographs were captured using an Orca ER camera 
(Hamamatsu, Inc.).  Colocalization of nanoparticles with lysosomes was 
analyzed by Metamorph, version 6.2. 
 
Development of Cell Sample Prep Method for SIMS Imaging: A cell 
sample preparation method was designed for SIMS imaging of 
nanoparticles in cells.  A polished silicon disk was wiped clean several 
times with an ethanol-dampened, lint-free cloth.  Residual dust was 
removed with pressurized nitrogen.  The disk was placed into a 35-mm 
petri dish and covered with a fibronectin solution (25 ug/mL, Sigma) in 
PBS.  After 3 hours at 4°C, the disk was removed, r insed with PBS and 
placed in a 35-mm petri dish.  A10 rat aorta smooth muscle cells (ATCC) 
maintained in DMEM containing 10% FBS at 37°C in a 5% CO2 incubator 
were seeded onto the disks at density of 1200 cells/cm2.  The disks were 
placed back into the incubator for 48 hours.  The samples were then 
rinsed in PBS and fixed in 1% formaldehyde in PBS for 4 hours.  The 
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samples were rinsed in PBS, then DI H2O and were allowed to dry in the 
laminar hood for 4 hours. 
TOF-SIMS (time of flight secondary ion mass spectrometry) was 
used to analyze the cell samples.  TOF-SIMS experiments were 
performed on an Ion-TOF IV instrument equipped with both Bi (Bin+, where 
n = 1 to 7) and SF5+ primary ion beam cluster sources.  The analysis 
source was a pulsed, 25 keV bismuth cluster ion source (Bi3+), which 
bombarded the surface at an incident angle of 45 degrees to the surface 
normal.  The target current was maintained at approximately 0.3 pA (± 
10%) pulsed current with a raster size of 200 µm x 200 µm for all 
experiments.  Both positive and negative secondary ions were extracted 
from the sample into a reflectron-type time of flight mass spectrometer.  
The secondary ions were then detected by a microchannel plate detector 
with a post-acceleration energy of 10 kV.  A low energy electron flood gun 
was utilized for charge neutralization in the analysis mode.  Each 
spectrum was averaged over a 60 s time period, with a cycle time of 100 
µs.  These conditions resulted in accumulated Bi3+ ion doses that were 
well below 1013 ions/cm2. 
 
Statistical Analysis: Statistical evaluation of data was performed using an 
analysis of variance (single-factor ANOVA).  Tukey’s test was used as a 
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post hoc analysis to assess the significance of differences.  A value of p < 
0.05 was accepted as significant. 
 
4.3 Results and Discussion 
Preparation of Fluorinated-fluorescent Nanoparticles: Fluorinated-
fluorescent nanoparticles were prepared using a free radical 
polymerization method, similar to what has been described previously.68  
Nanoparticles were conjugated with aninooxy-LABL peptide using an 
oxime formation strategy, resulting in a conjugation efficiency of 93.8 % ± 
0.05 % as measured by HPLC.  Dynamic light scattering showed a mean 
particle diameter of 440 nm ± 4.3 nm for the unconjugated NPs and 354 
nm ± 10 nm for the LABL-NPs (Table 4.1). 
 
Table 4.1: Dynamic light scattering and zeta potential data for 
Nanoparticles 
 Diameter (nm) Polydispersity Zeta Potential (mV) 
NP 440 ± 4.3 0.21 ± 0.019 -5.08 ± 0.86 
LABL-NP 354 ± 10 0.167 ± 0.083 -10.03 ± 3.27 
 
The polydispersities for the particle samples were 0.21 ± 0.019 for the 
unconjugated NPs and 0.167 ± 0.083 for the LABL-NPs, and the 
measured zeta potentials were -5.08 mV ± 0.86 mV and -10.03 mV ± 3.27 
mV for the unconjugated NPs and the LABL-NPs, respectively.  The 
observed decrease in NP size after conjugation with the LABL peptide 
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could be due to increased colloidal stability arising after conjugation due to 
the increased surface charge magnitude, which results from the presence 
of anionic amino acid residues in the LABL peptide.  Fluorinated groups 
on the NPs surface would be extremely hydrophobic, which might cause 
agglomeration, and hence an increased observed particle size for the 
unconjugated NPs.  Presumably, these hydrophobic interactions are 
mitigated by the presence of the LABL peptide, which decreases the 
tendency of the NPs to agglomerate and hence the observed particle size. 
 
Binding and uptake of nanoparticles in cells: Proinflammatory cytokines 
such as TNF-α have previously been shown to upregulate the expression 
if ICAM-1.95  HUVECs were incubated with 1,000 U/ml of TNF-α for 24 hrs 
to induce overexpression of ICAM-1.  HUVECs, with or without ICAM-1 
upregulation, were incubated with anti-ICAM-1-FITC, which resulted in an 
approximately 32 x increase in ICAM-1 expression compared to HUVECs 
incubated in medium without TNF-α.  The result confirmed the 
overexpression of ICAM-1 and validated the use of this cell line for this 
study (Figure 4.4). 
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Figure 4.4: Upregulation of ICAM-1 expression in HUVECs incubated with 
TNF- α, as measured by the fluorescence intensity of anti-ICAM-1-FITC 
antibody.  The results suggested an approximately 32 x increase in ICAM-
1 expression after incubation with TNF- α.  Error bars represent the 
standard deviation, with n=3. 
 
Nanoparticles conjugated with LABL peptide were rapidly taken up 
by HUVECs, as determined by fluorescence measurements after 
incubation for several time points (Figure 4.5). 
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Figure 4.5: Normalized fluorescence intensity of LABL-conjugated NPs 
and non-conjugated NPs in HUVECs.  The results suggested a much 
greater normalized fluorescence intensity for the LABL-conjugated 
nanoparticles, most likely due to binding facilitated by the LABL peptide.  
Data are presented by mean ± standard deviation.  *p<0.05. 
 
The normalized fluorescence intensity of the LABL-NPs was 
approximately 30 times greater after any incubation time (5 min to 60 min) 
than the normalized fluorescence intensity of the non-conjugated NPs, 
most likely due to binding to ICAM-1, which was facilitated by the LABL 
peptide.  The enhanced binding of nanoparticles to ICAM-1 mediated 
through LABL and similar peptides has been described by others.72, 96  
Optical images showing fluorescence at several different time points 
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corroborate the quantitative fluorescence measurements (Figure 4.6), 
where nanoparticles (green) can be seen around cell nuclei (blue). 
 
Figure 4.6: HUVECs after incubation with non-conjugated NPs and LABL-
NPs.  The results suggested that conjugation with the LABL peptide 
increases uptake of the particles into the cells. 
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 Colocalization of NPs with lysosomes was analyzed using 
fluorescence imaging (Figure 4.7).  Lysosomes are labeled red and NPs 
appear green.  The results suggested that neither the LABL-conjugated 
NPs, nor the non-conjugated NPs, were trafficked to lysosomes, which 
would appear yellow in the image.  This could be due to the large size of 
the nanoparticles (approximately 300 nm), which might be too large for 
endocytosis and/or lysosome trafficking.  Alternatively, particles could be 
bound to the surface of cells.  This result could be confirmed with SIMS 
analysis, which will analyze the surface of the cells and the internal 
composition of the cells by depth profiling. 
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Figure 4.7: Colocalization of untargeted and targeted nanoparticles with 
lysosomes. Lysosomes were stained with Texas red dextran, and cell 
nuclei were stained with DAPI (blue). Colocalization of nanoparticles 
(green) with lysosomes would appear yellow. The results suggested that 
the nanoparticles were not incorporated within the lysosomes. This could 
be due to their large size (approximately 300 nm). We hypothesize that 
the particles were internalized via endocytosis, but were not incorporated 
into the lysosomes. 
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Cell Sample Preparation for SIMS Imaging: A sample preparation method 
for SIMS imaging of cells was developed using A10 rat aorta smooth 
muscle cells as a model cell line.  Fixed A10 cells on silicon disks were 
imaged using a TOF-SIMS instrument equipped with an SF5 sputter 
source and a Bi3+ analysis source.  Cells were distinguishable before 
sputtering, but the surface contained many ions that would suggest the 
presence of residual salts, amino acids and proteins deposited from the 
growth medium and during substrate preparation (Figure 4.8).  Images 
acquired after sputtering show less deposited material and greater 
contrast between the cells and the surrounding substrate.  Amines, 
phosphates, and cholesterol are resolvable on the cell surfaces.  The 
results suggest that this sample preparation method is suitable for 
producing high-resolution SIMS images of eukaryotic cells and may have 
applications in biomedical imaging.  By incubating cells with an imaging 
probe that targets a specific cell surface antigen of interest; this technique 
could be used for in vitro diagnostic applications. 
 91
 
Figure 4.8: TOF-SIMS images of A10 rat aorta smooth muscle cells grown 
on a silicon substrate.  Panels (A) and (B) were imaged before sputtering 
with SF5, and (C) and (D) were imaged after sputtering.  (A): Dark purple – 
amino acids; Light purple – sulfates; Green – phosphates.  (B): Yellow – 
phospholipids; Blue – amino acids.  (C): Yellow – amines and phosphates; 
Green – amines; Red – phosphates; Blue – silicon substrate.  (D): Yellow 
– amino acids and phosphates; Green – cholesterol, amino acids and 
phosphates; Blue – silicon substrate. 
 
 
4.4 Conclusions 
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Fluorinated-fluorescent nanoparticles with the potential for use as both an 
optical fluorescence imaging probe and a secondary ion mass 
spectrometry (SIMS) imaging probe have been described.  Nanoparticles 
were conjugated with an ICAM-1 targeting ligand (LABL peptide) and 
showed enhanced binding to ICAM-1 expressing HUVECs when 
compared to non-conjugated particles.  Nanoparticles were not shown to 
appreciably accumulate in lysosomes, possibly due to their large size.  
Additionally, a cell sample preparation method for SIMS imaging was 
developed using A10 rat aorta smooth muscle cells on a silicon substrate 
as a model.  The images showed enhanced detail and less deposited 
material from the growth media after sputtering with SF5, and areas 
containing amino acids, phosphates, phospholipids, and amines were 
easily distinguished from the silicon background.  Present work is 
examining the suitability of fluorinated-fluorescent nanoparticles as SIMS 
imaging probes, which could be useful for diagnostic applications.  Future 
work should examine the use of fluorinated-fluorescent nanoparticles as 
an optical fluorescent imaging probe and a SIMS imaging probe in 
samples of pathological interest. 
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Chapter 5 
Conclusions and Future Directions 
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Fluorinated compounds have many applications in medicine, including 
oxygen transport, drug delivery vehicles, and contrast agents in medicine 
due to fluorine’s unique chemical and nuclear properties.  Fluorinated 
compounds have been used in microbubble contrast agents for ultrasound 
imaging, positron sources for PET imaging, and as an imaging probe in 
19F MRI.  Additionally, fluorinated organic compounds generate a high 
ionization yield of fluorine in secondary ion mass spectrometry (SIMS), 
which is gaining recognition as an in vitro cellular imaging technique.  This 
suggests that fluorinated SIMS “chromophores” could be developed for 
diagnostic imaging that target specific cell markers. 
 The goal of this work has been to develop a fluorinated 
nanoparticle platform technology that could be used for multiple 
biomedical imaging techniques, including in vivo and in vitro diagnostic 
imaging.  Fluorinated nanoparticles were synthesized from one of two 
fluorinated monomers, as well as a hydrophilic monomer and hydrophilic 
crosslinker to enhance the aqueous colloidal stability of the nanoparticles.  
Nanoparticles were then characterized to determine their chemical 
properties, colloidal stability, and suitability for use as a 19F MRI and SIMS 
contrast agent.  Particle sizes were measured using small angle neutron 
scattering and dynamic light scattering, nuclear magnetic resonance 
signal was measured using 19F NMR, and chemical functional groups 
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were determined using FTIR.  Particle size and structure were also 
examined using scanning electron microscopy and transmission electron 
microscopy.  The results suggested that nanoparticles are colloidally 
stable, exhibit a strong 19F NMR signal and a high fluorinated ion yield in 
SIMS, and contain functional groups that would facilitate conjugation with 
antibodies or other ligands for targeted nanoparticle delivery to 
pathological tissues of interest for imaging. 
 Nanoparticles were also developed for bimodal optical fluorescence 
imaging and SIMS imaging by incorporating a fluorescent functionality 
within the particles.  The fluorescent-fluorinated nanoparticles were 
conjugated with LABL peptide, which binds to ICAM-1 on the surface of 
endothelial cells to facilitate T-cell recruitment to sites of inflammation.  In 
vitro cell uptake studies show enhanced binding and uptake of LABL-
conjugated fluorescent-fluorinated nanoparticles compared to non-
conjugated nanoparticles, suggesting that this technique could be used as 
a targeting mechanism for cellular imaging.  A cell preparation method 
was also designed for SIMS imaging, which showed great cellular detail. 
Current work is examining the suitability of fluorinated-fluorescent 
nanoparticles as SIMS imaging probes for diagnostic imaging using the 
cell preparation method designed for this work. 
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 Future work with this nanoparticle technology platform should 
further examine the potential use of fluorinated nanoparticles and MRI 
contrast agents.  This would include phantom imaging of nanoparticle 
suspensions at different concentrations, followed by in vivo animal 
imaging.  Furthermore, nanoparticles could be conjugated with targeting 
ligands to facilitate binding to pathological sites for imaging applications, 
such as tumors or atherosclerotic plaque.  Additionally, linear fluorinated 
polymers, which were initially created as a control group, could be 
evaluated for their potential use in imaging applications.  Future work in 
the area of SIMS imaging and optical fluorescence imaging should 
examine the use of ligand-conjugated nanoparticles to probe pathological 
samples of interest to evaluate the diagnostic utility of these particles for 
clinically-relevant imaging of biopsied tissues and cells. 
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Appendix A 
Nuclear Magnetic Resonance (NMR) and Magnetic Resonance 
Imaging (MRI) 
  
Nuclear magnetic resonance is a phenomenon observed in atomic nuclei 
with net unpaired nuclear spins.  Spin is a fundamental quantum 
mechanical property of all elementary particles.  It is mathematically 
similar to angular momentum; however spin can only have discrete values 
in one of two spin states.  Both of these states have the same energy, and 
hence are degenerate.  Analogous to a spinning charged particle in 
classical physics, an elementary particle with a net spin and a charge also 
possesses a magnetic moment.  The magnetic moment interacts with an 
external magnetic field, generating a torque on the particle.10, 25 
W = µ × Bo  
where W is the torque, µ is the magnetic moment vector, and Bo is the 
external magnetic field.  In the absence of other effects, the torque would 
rotate the magnetic moment into alignment with the external magnetic 
field.10, 25  The nucleus also possesses a net angular momentum due to 
spin, so this alignment does not occur immediately.  Instead, the magnetic 
moment precesses around the external field axis at the Larmor frequency, 
as shown in Figure A.1. 
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Figure A.1: Precession of a magnetic dipole in a magnetic field.  The 
external magnetic field, Bo, exerts a torque on the magnetic moment 
(magnetic dipole) that would normally tend to make it align with the 
external magnetic field.  However, the nucleus has angular momentum, so 
the magnetic moment precesses at the Larmor frequency (vo) around the 
external magnetic field (Bo).10, 25 
oo B⋅= γν  
where νo is the Larmor frequency, and γ is the gyromagnetic ratio of the 
nucleus.  The gyromagnetic ratio is given by the following equation: 
γ = µ
L
∝
q
m  
where L is the angular momentum of the nucleus, q is the charge, and m 
is the mass of the nucleus.10, 25  The value of the gyromagnetic ratio 
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increases with increasing nuclear charge (atomic number) and decreases 
with increasing mass (mass number).  It is worth noting that atomic nuclei 
without unpaired nuclear spins (i.e. possess an even number of nucleons) 
do not possess a magnetic moment and hence do not exhibit nuclear 
magnetic resonance.  Gyromagnetic ratio values of physiologically 
relevant atomic nuclei are listed in table A.1.25 
Table A.1: Gyromagnetic ratios for 
atomic nuclei of physiological interest. 
Nucleus γ (MHz/T) 
1H 42.58 
13C 10.71 
19F 40.08 
23Na 11.27 
31P 17.25 
 
 Because of the two possible degenerate states of the nuclear spin, 
magnetic moments will align themselves with the external magnetic field in 
either a parallel or anti-parallel state.  The anti-parallel state is slightly 
more energetic than the parallel state, thus slightly more nuclei will be in 
the parallel state than the anti-parallel state.10  This generates a net 
magnetic moment (Mo) within the tissue that precesses at the Larmour 
frequency.  The energy difference between the two spin states is given by: 
∆E = −γhBo
2pi  
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where h is the Planck constant.25  The ratio of parallel to anti-parallel spin 
states is given by: 
n+
n
−
= e
−∆E
kBT
 
where kB is the Boltzmann constant and T is the temperature.25  Because 
the energy difference between the two degenerate spin states is much 
smaller than the kBT energy, this equation can be expanded to give an 
expression for Mo in the tissue: 
Mo ≈
nµ2Bo
kBT  
where n is the total spin density (n+ + n-).25  Thus, the equilibrium 
magnetization vector increases in magnitude as the strength of the 
external magnetic field increases.  This sets the scale for the magnitude of 
the NMR signal, and is the primary motivation for doing MRI at high 
magnetic field strengths. 
 As described in Chapter 1, a typical MRI experiment consists of a 
transverse magnetic field that oscillates at the Larmor frequency of the 
nuclei of interest.  This causes the magnetization vector to “flip” in the 
direction of the transverse field.  If left alone, the flipped vector will decay 
back to its equilibrium position (Mo) in partial alignment with Bo.25  This 
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phenomenon is called free induction decay (FID) and occurs as an 
exponential decay function dependent on the T2 relaxation time.  As the 
amplitude of the transverse magnetic field is increased, the “flip angle” 
increases proportionately.  Flip angle notation is often used in MRI, where 
a 90º pulse would mean a transverse magnetic field pulse with sufficient 
amplitude to “flip” the magnetization vector 90º.25 
 MRI pulse sequences incorporating several different flip angle 
magnetic pulses are often used during imaging to enhance the NMR 
signal.  One common pulse sequence is the spin echo pulse sequence, 
which begins with a 90º pulse and finishes with a 180º pulse several 
precession periods later.  An illustration of this sequence is shown in 
Figure A.2. 
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Figure A.2: Spin echo pulse sequence.  A 90º pulse is applied to Mo (2), 
which is then allowed to precess for several periods.  As this occurs, Bo 
inhomogeneities cause nuclei to precess at slightly different frequencies 
(3), thereby causing the magnetization vector to dephase.  After a 180º 
pulse (4), the vector rephases as the component vectors acquire a 
negative phase.  This produces a spin echo (5), overcoming the 
dephasing limitations of Bo field inhomogeneities.25 
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After the initial 90º pulse, the magnetization vector is allowed to precess 
for several periods.  As the precession occurs, some nuclei begin to 
precess at different rates due to inhomogeneities in the Bo external field.  
This causes the magnetization vector to dephase into several vectors that 
precess at slightly different rates and have smaller magnitudes.  By 
applying a 180º pulse, all vectors are converted to a negative phase angle, 
meaning that the vectors that were precessing at a faster rate are now 
behind the vectors precessing at a slower rate, causing the vectors to 
rephase as precession continues.  This produces a spin echo, which can 
be measured by the MRI solenoid.  This technique is the work horse of 
MRI because it can be used to overcome inhomogeneities in the Bo 
external field.25 
 The dynamics of the magnetization produced by nuclear magnetic 
dipoles in an external magnetic field have been modeled by the Swiss 
physicist Felix Bloch in 1946.25  The Bloch equations include terms for 
precession, as well as exponential relaxation based on the T1 and T2 
relaxation times.  They are empirical equations designed to reproduce 
experimentally observed dynamics. 
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dMx
dt
= γBoMy −
Mx
T2
dMy
dt
= −γBoMx −
My
T2
dMz
dt
= −
Mz − Mo
T1
 
where Mx, My, and Mz are the three spatial components of the 
magnetization vector, and Mo is the equilibrium magnetization.25  The 
preceding equations describe relaxation and precession when only the 
external magnetic field is acting on the nuclear magnetic dipole, and does 
not account for the transverse magnetic pulse.  To include this 
phenomenon, one has to convert the equations to a rotating frame of 
reference so that the oscillating field appears to be constant.25 
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In this set of equations, ωrot is the apparent precession rate in this rotating 
frame of reference, and ωT is an equivalent to a precession frequency 
around the transverse magnetic field (ωT = γBT).25 
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Appendix B 
Secondary Ion Mass Spectrometry (SIMS) 
 
Secondary ion mass spectrometry (SIMS) is a surface analysis technique 
that is widely used to analyze the elemental composition of thin films.16  
Until recently, its use in biological samples has been limited by the 
complex nature of biological systems and by the imprecision of available 
SIMS technology.  Current research in biological applications of SIMS 
suggests that this technique holds promise as a means to generate both 
qualitative and quantitative pharmacological and toxicological data from 
living systems.14, 90, 97 
SIMS is a technique that depends on the sputtering of secondary 
ions from the surface of the sample of interest using a beam of highly 
charged particles, as shown in Figure B.1.16 
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Figure B.1: Diagram of SIMS.  The sample surface is bombarded with 
primary ions, causing material to be desorbed from the surface, some of 
which is ionized and collected by the mass spectrometer. 
 
The impact from this primary ion beam causes secondary ions and 
polyatomic fragments to be ejected from the surface, where they are 
collected and analyzed by a mass spectrometer.  Several different primary 
ion species are useful in SIMS, including Cs+, O2+, O, Ar+, and Ga+ at 
energies between 1 keV and 30 keV.16  The number of secondary ions 
produced as a function of sputtering is quantified by the sputter yield, 
which is the ratio of the number of atoms desorbed from the surface to the 
number of impinging primary ions.  This value typically falls between 5 and 
15 secondary ions per primary ion.16  The secondary ion yield is the 
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fraction of desorbed material that becomes ionized and varies depending 
on the ionization potential of the species being ionized.  Correlations 
between ionization potential and secondary ion yield are not exact and 
depend on the sample matrix and the sample itself.16 
Sputtering effects can be described by the collision cascade model, 
where a high energy primary ion impacts a surface particle, transferring 
energy and momentum to an adjacent surface particle.  This triggers a 
series of binary collisions, resulting in a change in the lattice structure of 
the sample and desorption of surface material.13  Cluster ion sources can 
be used in SIMS to generate different sputtering effects.  Typical 
monatomic primary ions (e.g. Cs+, Ar+, Ga+) impact the surface at high 
energy, causing a large shift in the lattice structure, while only a small 
amount of material is desorbed from the surface.  Conversely, a cluster 
ion primary beam (defined as any polyatomic ion species) has energy 
distributed to each atom in the cluster, thereby having a net effect of low 
energy primary ions impacting the surface of the sample.  This produces 
less lattice disruption and causes more material to be ejected from the 
surface.13 
As an example of cluster ion verses a monatomic ion as a sputter 
source, consider a 15 keV Ga+ primary ion verses a 15 keV C60+ primary 
ion.  The gallium ion will impact the surface with a kinetic energy of 15,000 
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eV, causing lattice disruption deep into the sample and minimal desorption 
of material.13  In comparison, the 15,000 eV of the C60 ion will be 
distributed between 60 atoms, giving each carbon atom 250 eV of kinetic 
energy.13  The C60 sputtering is localized to a depth of a few nanometers, 
causing minimal lattice disruption and a greater sputter yield.  This is 
shown in Figure B.2. 
 
Figure B.2: The effect of a 15 keV Ga+ ion (A) verses a 15 keV C60+ ion (B) 
in SIMS.  The Ga+ ion penetrates deeper into the substrate and at higher 
energy, causing lattice disruption and interlaminar mixing.  The C60+ 
cluster ion has 250 eV per atom, which causes less lattice disruption and 
more material to be desorbed from the surface.13 
 
In SIMS imaging, the primary ion beam raster scans the surface of 
the sample, collecting a mass spectrum for each pixel with a lateral 
resolution of about 100 nm.13  The raw mass spectral data can be 
analyzed for specific ions of interest, which can be used to generate a 
two-dimensional compositional map of the sample surface (Figure B.3).  
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This technique can be used to generate images of biological samples 
showing the spatial distribution of compounds of interest, with a resolution 
of about 100 nm.13  This is especially attractive for cell and tissue 
samples, which can be analyzed for specific biomarkers or targeting 
agents that have been introduced to enhance contrast. 
 
Figure B.3: Schematic of SIMS imaging.  A cell sample is raster scanned 
in the SIMS instrument by the primary ion beam, which generates mass 
spectral data for each pixel.  A two-dimensional composition map is 
generated from the raw data, which is effectively an image of the sample 
surface. 
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Appendix C 
Small Angle Neutron Scattering (SANS) 
 
Small angle neutron scattering (SANS) is a technique used to characterize 
structures in the nanometer size range and is ideally suited for studying 
polymers and colloids.  Neutron scattering has several advantages over 
other scattering techniques such as X-ray scattering and light scattering.  
For instance, x-rays are scattered by the electrons surrounding a 
nucleus.98  Consequently, heavy atoms (such as lead, mercury, etc.) 
scatter x-rays more efficiently than light atoms like carbon, oxygen and 
hydrogen.  These lighter elements are the primary constituents of 
polymers, rendering them near invisible to x-rays.  Neutron scattering is 
advantageous over light scattering because of a technique called contrast 
matching, in which isotopic differences in neutron scattering cross 
sections are exploited to enhance the contrast of the particles in the 
colloid with the background medium.98  Additionally, in contrast to photons, 
neutrons interact with matter via nuclear forces rather than electrical 
forces, therefore they can penetrate deeper into matter.98  The only 
disadvantage of neutron scattering is the relatively low neutron flux 
compared to other scattering techniques.  Typical x-ray synchrotrons 
produce x-ray photons at a flux of 1018 photons per second per square 
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millimeter, while a typical neutron flux is on the order of 104 neutrons per 
second per square millimeter.98 
Neutrons are generated for neutron scattering experiments with 
either nuclear reactors or spallation sources.  Reactor neutrons are 
produced in a nuclear reactor by the fission of uranium fuel.98  Spallation 
neutrons are produced using particle accelerators that bombard a heavy 
metal target with high-energy protons, causing neutrons to be ejected from 
the metal nuclei.  Neutrons produced from these sources are “hot,” with 
energies on the order of 10-100 MeV.98  In order to be suitable for 
scattering experiments, neutrons must be made “cold.”  This is done by 
bringing them into thermal equilibrium with a moderating material that has 
a high scattering cross section, such as liquid hydrogen.  This reduces the 
energy of the neutrons to about 5 MeV, which have a wavelength close to 
the typical interatomic distance and are therefore appropriate for 
scattering experiments.98 
Neutron scattering occurs within a sample via elastic and inelastic 
scattering.  In elastic scattering, there is no energy transfer between the 
incident neutron and the nucleus, thus only the direction of the neutron 
changes.98, 99  With inelastic scattering, some of the kinetic energy is 
transferred to the nucleus, thus the magnitude of the neutron momentum 
vector changes in addition to its direction.98, 99  This scattering depends on 
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the nuclear interaction potential between the neutron and the nucleus and 
decreases as the distance between them increases.  This potential is very 
short range and decreases to zero at around 10-15 meters, which is much 
shorter than the wavelength of the cold neutrons (around 10-10 meters).98  
As a result, the nucleus acts as a point scatterer.  An incident wave of 
neutrons has the wavefunction:99 
ψ i = e ikz  
where k is the incident neutron wave vector that points along the trajectory 
of the neutron and has magnitude 2pi/λ, where λ is the wavelength of the 
neutron.  In this equation, z is the distance from the nucleus, and i is the 
imaginary unit.  Because the nucleus acts as a point scatterer, the 
scattered wave will be spherically symmetrical with the wavefunction:99 
ψs =
−b
r
e i
′ k r
 
where b is the nuclear scattering length, r is the distance from the nucleus, 
and k’ is the scattered neutron wave vector.  The scattering length varies 
randomly across the periodic table, as well as between isotopes of the 
same element.98, 99  This property is often exploited to enhance contrast 
between particles in a colloid and the surrounding medium.  For example, 
hydrogen has a scattering length of -3.74 x 10-5 Å, and deuterium has a 
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scattering length of 6.67 x 10-5 Å.100  By replacing an aqueous medium 
with deuterium oxide, the contrast between the colloidal particles and the 
aqueous medium can be enhanced.  This technique is one of the key 
advantages of neutron scattering over other scattering techniques.  A 
diagram of elastic neutron scattering is shown in Figure C.1.98 
 
 
Figure C.1: Elastic neutron scattering from a fixed nucleus in space. 
 
The incident and scattered wave vectors are given by k and k’, 
respectively.  The scattering vector is given by Q, which is the vector 
difference between k and k’.98 
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For an assembly of nuclei in space, the intensity of neutrons 
scattered at small angles is given by:99 
I(Q) = ρ(r)e iQ⋅rd3r∫
2
 
Where ρ(r) is the scattering length density.  In samples such as colloidal 
particles suspended in solution, the particles typically have a uniform 
scattering length density and are dispersed in a medium that also has a 
uniform scattering length density.  In this case, the scattering intensity can 
be given by:99 
I(Q) = (ρp − ρm )2 N p e iQ⋅rd3rVp∫
2
 
where ρp and ρm are the scattering length densities of the particles and the 
matrix, respectively.  The number of particles is given by Np, and the 
integral is taken over the entire volume, Vp.  The integral term is called the 
form factor and is dependent on the geometry of the particles.  For many 
simple shapes (e.g. spheres), the form factor can be easily obtained.  For 
instance, the form factor for a sphere of radius r is given by:99 
( )
( )
2
3
)cos()sin(3)( 




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= Qr
QrQrQrQP
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Other form factors exist for cylinders, ellipsoids, and more complicated 
geometries. 
 Raw SANS data are collected as intensity over polar space.  For 
isotropic SANS experiments where intensity only changes as a function of 
radius from the origin in polar space, mathematical reduction techniques 
can be used to generate one-dimensional data sets of I(Q).69  These data 
can be analyzed using a variety of model-independent techniques, as well 
as fit with various models that consider the geometry of the particles and 
the nature of their interactions.  From these, one can derive information 
about particle size, polydispersity, molecular weight, and other particle 
properties.69 
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